Advances in Cancer Biology - Metastasis 4 (2022) 100033

Contents lists available at ScienceDirect

Advances in Cancer Biology - Metastasis

journal homepage: www.journals.elsevier.com/advances-in-cancer-biology-metastasis

Immunotherapy for neuroblastoma using mRNA vaccines

Tanvir Ahmed

Department of Pharmacy, Brac University, 66 Mohakhali, Dhaka, 1212, Bangladesh

ARTICLE INFO

Keywords:
Neuroblastoma
Immunotherapy
mRNA vaccine
Cancer

ABSTRACT

In children, neuroblastoma seems to be the most frequent form of tumor found in the extracranial region, with a wide range of medical outcomes ranging from reduction of the tumor volume with time to even developing into a metastatic form and death, regardless of treatment. mRNA vaccines have emerged as a potential cancer treatment platform and could be used as a treatment of neuroblastoma as well. mRNA vaccines, whether naked or loaded with a carrier, proficiently express the antigens of the tumor in APCs after the process of immunization which facilitates the stimulation of the APCs and innate immune reaction. The characteristics such as elevated effectiveness, harmless administration, quick expansion abilities, and efficient manufacturing allows the mRNA cancer vaccines outperform other traditional vaccination platforms. This review focuses on the mRNA vaccine for the immunotherapy of neuroblastoma and gives an overview based on the recent literature available.

1. Introduction

The best cancer immunotherapy tries to manipulate the immune system to effectively eliminate cancerous cells [1,2]. However, cancer vaccines' anti-tumor effectiveness remains limited, in part due to lacking delivery of the antigenic markers and the associated adjuvants to where the immune response remains spatially and transiently coordinated [3–5]. Another important stumbling block is ensuring that these functional components are released in a controlled manner at the intended action locations [2,3,5,6]. In spite of the fact that a few advance has been made in this field, effective immunization conveyance with exact dosing and on-demand discharge is greatly troublesome [4,7,8]. The vaccination against cancer might be advantageous because of the development of efficient vaccine delivery platforms on the molecular mechanisms which are programmable [9–11]. To achieve notable effects, the immunotherapy for cancer treatment greatly depends on the monoclonal antibodies, the structural proteins, and the therapeutic agents which are the cells [5,8]. However, the therapeutic advantages of the immunotherapy against cancer must be improved, as several patients do not yet react well to current therapies, and their illnesses may return after momentary switch [9,12]. The methods that use RNA have opened up new avenues for cancer treatment [8,11]. Furthermore, significant attempts have been made to use RNA in the manufacturing of vaccines [7]. RNA vaccines boost adaptive immunity by encoding tumor-associated or particular epitopes [9–11]. This adaptive immune response has the potential to eliminate or reduce tumor volume [7,9,10]. It's critical to create RNA transfer methods that can get through the lipid bilayer and into the cytoplasm, where they can be translated into functional proteins [12–14]. The mRNA which are loaded in ex vivo into the dendritic cells and the mode of inoculation of the bare RNA with or without a carrier are two significant delivery techniques [9,10]. The research of cancer immunotherapy using natural killer (NK) cells has reached a pivotal point [12,14,15]. In spite of the reality that these medicines have not however maintained the same level of clinical efficacy as receptive T cell treatments, initial preclinical and clinical progressions with NK cell treatments have fueled intrigued in assisting their improvement [16,17].

Neuroblastoma (NB) is the foremost predominant deadly tumor seen in children, affecting generally 6% out of all cancer types found in children and having a 1/70,000 rate in children beneath the age of 15. It's a neuroblastic tumor caused by a disturbance within the signaling pathways that control the arrangement of ganglion cells which are primitively sympathetic [18,19]. It's also known as ganglio neuroblastoma and ganglioneuroma [20,21]. Patients with NB are divided into three forms; low risk, intermediate risk, and high risk categories based on their medical phase, age of detection, histology of the tumor, MYCN oncogene extension, histology, and chromosomal ploidy [22,23]. In high-risk NB, recurrence is frequent. The frequent sites of metastasis be located in the bone marrow, bone structure, lymph nodes and finally in liver [24–26]. Diagnostic and therapeutic variance and prognosis are typical characteristics of NB, and genetic differences such as MYCN duplication and 1p or 11q deletions can be linked to them. In the most aggressive cancers, the MYCN oncogene is amplified [27–29]. For all of these reasons, developing better and more sophisticated immunotherapies is a top priority [30–32].

Tumor cells exhibit immunogenicity similar to other infectious

E-mail address: tanvir.ahmed6@g.bracu.ac.bd.

https://doi.org/10.1016/j.adcanc.2022.100033
Received 11 October 2021; Received in revised form 17 February 2022; Accepted 21 February 2022
Available online 4 March 2022

Abbreviations:

mRNA	messenger ribonucleic acid
NB	neuroblastoma
APC	antigen presenting cells
NK cells	natural killer cells
TAA	tissue associated antigen
TMB	tumor mutational burden
MDSC	myeloid derived suppressor cell
TIL:	tumor infiltrating lymphocyte
ASCT	autologous stem cell transplantation
mAb	monoclonal antibody
IL:	interleukin
GM-CSF	granulocyte macrophage colony activation factor
TLR	toll like receptor
RIG	retinoic acid inducible gene
RIR	retinoic acid like receptors
MDA	melanoma differentiation associated
IFN	interferon
ssRNA	single stranded RNA
LNP	lipid nanoparticle
EMA	European medicines agency
FDA	Food and drug administration
MHC	major histocompatibility complex
CIT	cancer immunotherapy
ICI	immune checkpoint inhibitors
GEP	gene expression patterns
LUSC:	lung squamous cell
CYT	cytolytic activity
nsSNVs	non synonymous single nucleotide variants
CAR	chimeric antigen receptors

organisms, and they often stimulate a wide range of biological mechanisms [33–35]. The participation of a range of immune cells is required for immunoregulation. Tissue-associated antigens (TAAs) are generally accessible to the antigen presenting cells, such as oligodendrocytes and white blood cells, as the initial step in antitumor immunotherapy [36–38]. The condition of the microenvironment of tumor and the infiltration of components of the immune system are typically determining factors in the lifespan of tumor tissues and organs [39–41]. However, many lymphocytes in the TME do not play a helpful role, preferring instead to aid cancer immune evasion, resulting in a very complicated interplay between cancers and inflammatory processes [42–45]. Independent body or cell variation, such as tumor mutational burden (TMB), physiological status, microbiome, and other distinct characteristics, has a major influence on TME and immunization outcomes [46,47].

The elevated NBL tumor microenvironment is marked by the appearance of very minor number of tumor cells, which is termed as “cold” or “immune-deserted.” [48,49]. On the other hand, the chance of a cool tumor reacting to immunological therapy is contingent on strategies for converting it into “hot” tumors [50–52]. The genesis of the chilly phenotype is thought to be the formation of numerous immunomodulatory systems of the tumor and its environs, as well as MHC-I down regulation, regulatory T cell (T_{reg}) and myeloid derived suppressor cell (MDSC) growth, and reduced T cell toxicity of cells [53–55]. The NBL is infiltrated by immune system, particularly for low risk situations. TILs (tumor-infiltrating lymphocytes) have been linked to improved clinical outcomes [56,57]. Higher blood concentrations of granulysin, a cytotoxic T cell eector in, discovered in an incidence of unprompted NBL relapse suggest immunologic invasion as a factor in NBL remission [58–60]. In order to improve neuroblastoma treatment effectiveness, therapeutic intervention to enhance immunological invasion and identification may be necessary [61,62].

Surgery is used to treat high risk neuroblastoma, radiation, five to eight rounds of rigorous chemotherapy, together with platinum (Pt), alkylating agents, and topoisomerase agents which are often convoyed by autologous stem cell transplantation (ASCT)—and immunotherapy [63, 64]. The increased expression of disialoganglioside2 (GD2) among neuroblastomas and reduced protein concentration in the body tissue provides the foundation for GD2 focused immunotherapy [65,66]. Treatments with the recombinant mAb anti GD2 (ch14.18), and similarly the cytokines IL-2 and granulocyte macrophage-colony activation factor (GM-CSF) and isotretinoin, improved two years event-free (EFS) and increased survival in patients with high risk neuroblastomas [67,68]. Despite the fact that NBL has a severely immunomodulatory immunological environment, this effect was observed, demonstrating the feasibility of immune therapy in NBL [69–71]. The existing immunotherapeutic strategy is notably inefficient for rising illnesses. Additionally, osteomedullary malignant cancer affects the majority of people with increased neuroblastoma [72–74]. To figure out what separates survivors from non survivors, researchers must first figure out how effective cancer treatments work [75,76].

Immunizations are more complex to make than other immunotherapeutic solutions, and clinical reaction in patients is regularly poor [77–79]. Vaccines, while on the other side, are a promising cancer therapeutic option because they provide a targeted, safe, and tolerable treatment that also avoids chemoresistance and provides a long-lasting therapeutic response owing to memory b cells [80–82]. Cancer vaccines may be divided into four categories: vaccines which uses viral vector, tumor and immune cell constructed immunizations, peptide & nucleic acid-based vaccine. A DNA or RNA-based vaccine is a feasible choice for a variety of reasons [83–85]. For starters, it allows for the simultaneous injection of several antigens, evoking both body's immune and cell-mediated immunity, boosting the likelihood of tumor tissue eradication [64,66,69]. Furthermore, with exception of vaccines based on peptides, nucleic acids etc. are not constrained by the participant's HLA class. In the end, DNA- or RNA-based vaccines, like earlier vaccines, are harmless and well-tolerated [71,86,87]. Till recently, the bulk of RNA-based vaccines evaluated in clinical situations have used messenger RNA (mRNA) [45,47].

1.1. *mRNA vaccines*

As a consequence of substantial technological advancement and research spending over the last decade, mRNA is considered as a leading therapeutic intervention in the area of the development of vaccines and protein auxiliary therapy [2,3,45,47]. The usage of messenger RNA has numerous paybacks over constituent, live attenuated virus or dead virus, as well as vaccines based on DNA [2,3]. Initially, since mRNA is safe, non-assimilating system, there seems to be no chance of contamination or splice mutations [6,8]. Also, mRNA decays as a result of regular biochemical methods, and it's in vivo half-life may be manipulated by different changes and delivery strategies [14,15]. The intrinsic immunity of the mRNA can be quite less moderated to enhance the effectiveness and wellbeing. Furthermore, effectiveness: several alterations make mRNA more viable and extra translatable [20,21]. In vivo delivery can be made more effective by transforming mRNA into transport mechanism that allow for rapid uptake and activation in the cytoplasm [26,88]. Anti-vector defense is avoided since mRNA is the simplest genomic vector, and mRNA vaccines may be administered repeated times [27,28]. Finally, mRNA vaccination have the ability for rapid, low-cost, and reproducible production because to the excellent yield of in vitro transcriptional methods [16,17]. The field of mRNA vaccination is rapidly

developing; over the last few years, a significant quantity of experimental evidence has accumulated, and numerous human trials have commenced [6,8]. In this Review, we examine existing mRNA vaccination approaches, highlight recent findings, highlight hurdles and recent accomplishments, and provide future predictions for mRNA vaccines [30,31]. The results indicate that mRNA vaccines may unravel a lot of the problems that hamper vaccine research for transmittable diseases and cancer [89–91].

1.1.1. Current use of mRNA vaccines

mRNA vaccines are a potential substitute for traditional immunization techniques owing toward their greater effectiveness, ability to multiply quickly, and promise of low-cost production and harmless administration [20,92,93]. Yet, due to the volatility and inaccuracy of mRNA diffusion in vivo, their application was restricted till late [17,81,94]. Owing to recent developments in technology, many mRNA vaccination systems against transmittable diseases and various forms of cancer have revealed promising outcomes in experimental animals as well as in humans [93–95].

Because of its self-adjuvating ability, mRNA could take on characteristics analogous to the mRNA virus when employed by means of a transporter for foreign genes [2,96]. In this situation, APCs recognize mRNA, and the pattern recognition receptors (PRRs) TLR3 (Toll-like Receptor 3), TLR7 (Toll-like Receptor 7) and TLR8 (Toll-like Receptor 8) are activated as a result (Toll-like Receptor 8) [1,93,97]. The RNA can be a double molecule (dsRNA). Few Retinoic-acid-inducible gene I (RIG-I) like receptors (RLRs) can network directly through some Retinoic-acid-inducible gene I (RIG-I) like receptors (RIG-I) -like receptor sites in the cytoplasm (RLRs) [24,98,99]. RIG-I and MDA5 (melanoma differentiation associated 5) are two proteins that help APCs mature and produce pro-inflammatory cytokines and type I interferon (IFN). As a result of this process, the emergence of antigen precise humoral and cellular immune reactions occur [19,73,89]. Since peptides or protein antigens in subunit vaccinations are still unable to stimulate PRRs, adjuvants that could initiate and sustain adaptive immune reactions should be added to obtain the end objective of subunit vaccines acting out the body's natural immunity [25,76,86]. So, mRNA vaccines can yield meaningfully from its robust adaptive immune response and self-adjuvating traits and characteristics [40,90,100]. Single-stranded RNA (ssRNA) can excite dendritic cells in an antiviral state by distinguishing TLR7 and TLR8 during mRNA in vivo transportation [93,94].

The unsurpassed treatment aimed at an autoimmune disorder should precisely target innate immune cells without demanding extensive immune repression [20,92,93]. Numerous approaches to antigen-specific tolerance of t - lymphocytes also have been studied, with variable success [17,81,94].

One of most important breakthroughs in mRNA vaccine technology over the years have been in the areas of: 1) mRNA sequence editing, 2) advancement of simple, fast, and vast cGMP mRNA fabrication technologies, and 3) generation of extremely efficient and safe mRNA vaccine administration technologies [20,81].

1.1.2. Scope in cancer treatment

Sahin and colleagues were the first to employ tailored cancer vaccines which includes the neoepitope mRNA. They use high-throughput genotyping to recognize each exclusive somatic mutations in a patient's cancer cell specimen, a process known as mutanome discovery [4,40,54,92]. This allows the normal progression of individual patient neoepitope vaccines for cancer, and also the identification of non-self-antigen precise characteristics which should not be eliminated by systemic signaling pathways [20,56]. Recently, a prototype of the system was introduced: As per Kreiter and colleagues, a large fraction of non-synonymous tumor alterations were immunogenic when fed by mRNA and had been primarily detected by $CD4^+$ T lymphocytes [45,88,104]. They devised a computerized model for detecting MHC class II-restricted found a higher prevalence that may be used as vaccine immunomodulators based on these results. mRNA vaccines generating such neoepitopes reduced tumor growth inside the B16–F10 malignant tumors and CT26 colorectal cancer model organisms [12,17,81]. The clinical research carried out recently by Sahin and colleagues created tailored mRNA based on neoepitope immunizations designed for 13 participants having melanoma which are metastatic, the cancer with a greater frequency of genetic abnormalities and also neoepitopes [35,62,105]. Investigators utilized raw mRNA to inoculate humans against ten distinct neoepitopes intranodally. $CD4^+$ T lymphocytes reactions against the bulk of the neoepitopes were detected after months of observation, and there was a minimal rate of malignant illness68. Interestingly, an investigation of the identical strategy which used synthesized peptides instead of mRNA177 used immunogens achieved comparable findings [66,103,106]. Such latest researches, considered collectively, indicate to the potential usefulness of tailored vaccination technique [4,33,92].

1.2. Cancer immunotherapy

For patients with cancer, immunotherapy is a well-established and critical effective therapy. Considering the enormous research and clinical trial work committed to enhancing both endogenous and synthesized immunization techniques, focusing on essential issues and identifying hurdles to basic understanding and translational development is critical [54,107].

In past few years, cancer immunotherapy (CIT) has made significant strides, highlighting the existence of a significant relationship between the host immune response and cancer [4,33]. Regardless of the fact that CIT has been effectively utilized to cure a wide range of human cancers, these therapies assist only a tiny number of patients with some rather deadly diseases [20,56,88]. The immune system's complex and carefully regulated structure is most likely to blame for these findings. A lot of biological steps must be accomplished sequentially prior to efficient immune eradication of tumor cells, comparable to other sophisticated and well-designed processes [18,66].

A multitude of fail-safes, negative feedback mechanism, and milestones are also included into the mechanism, allowing for accurate positioning as well as the ability to withdraw and stop down an immune response [12,38,106]. However, cancer is the most prevalent, adaptable, and varied illness caused by a variety of genetic abnormalities that affect cell behavioral performance [34,35]. On the other hand, the gene mutations that are central to the oncogenic pathway might make the tumor cells appear increasingly foreign to the immune system, enabling for CIT [59,82].

Mutations in the clonality of cancer cells and/or the surrounding microenvironment can cause tumors to look varies in various people, and lesions can differ even within a particular patient [5,53,91]. Also, certain tumors occur as a consequence of chronic inflammation, whereas others can resist and/or co-opt an immune reaction in order to develop and propagate [55,108]. The resulting interplay with both evolving aspects of the human immune function and a nascent cancer can lead to a variety of results, including complete immunologic eradication of cancer, a never-ending wiggle between the two, or unmanaged tumor progression that has eluded an immune reaction [11,108,109].

1.3. Immunotherapy for neuroblastoma

Immunotherapy looks to be a promising treatment option for HR-NB patients. Combination therapy with GD2 specific monoclonal antibodies is now recommended for the remedy of high-risk neuroblastoma. The usage of GD2 specific monoclonal antibodies expressively elevates the persistence of patients and remains the benchmark of cure for this kind of cancer [28,56]. Simultaneously, owing to the drug's dose strength and general effectiveness, the usage of this technique of immunotherapy cannot be considered optimal due to the noteworthy adverse reactions [9,54]. Immunotherapy, however, presents an intriguing treatment approach for HR-NB since the administration of monoclonal antibodies

causes no accumulation or long-term damage [4,26,69]. In this respect, an intensive understanding of the natural characteristics of NB, the recognizable proof and investigation of atomic indicators on the cancerous cells, and the adjustment of progressive immunotherapy tactics to the treatment of high risk neuroblastoma are all basic steps within the improvement of viable neuroblastoma immunotherapy [3,49,59]. Fig. 1 shows the immunotherapeutic strategies for the treatment of neuroblastoma.

1.3.1. Immune invasion mechanisms

One of the foremost common ways for tumors to avoid safe disposal is by disturbing the adjust between effector and administrative cell compartments. TILs (tumor-infiltrating lymphocytes) are imperative players in antitumor resistance and cancer development control [11,43]. Amid the early stages of cancer, effector cells which are toxic to the cells such as $CD8^+$ T lymphocytes prevail; be that as it may, as tumor tissues develop, juvenile cells of the natural resistant framework such as tumor associated macrophages (TAMs), and myeloid-derived silencer cells (MDSCs) slowly dwarf these cells, securing immunosuppressive phenotypes [55,113]. A few examinations have appeared that the nearness of different penetrating lymphocytes in essential tumors is connected with moved forward clinical results. In spite of the fact that the centrality regarding the cells in neuroblastoma patients has however got completely caught on, ponders of strong tumors have driven to the disclosure of safe cells with both favorable and unfavorable clinical results [5,25,103].

1.3.2. Overcoming the immunosuppressive tumor microenvironment

Immunotherapeutic strategies to cancer treatment have gotten a part of consideration in later decades. We made hereditarily altered T lymphocytes coordinated towards specific antigens, particularly CART cells, based on overpowering information supporting the resistant system's imperative inclusion in tumor disposal coupled with modern atomic methods [48,114]. T lymphocyte recognizes the TAAs without utilizing MHC, overcoming variations from the norm in antigen preparing and introduction caused by cells of the tumor site, which is one such suppressive mechanism for early escaping of the tumor mass [7,77]. Clinical adequacy of CART cells has been built up in an assortment of hematological malignancies, be that as it may the same procedure for strong tumors is less investigated. In a couple of clinical considers for NB patients with destitute comes about, CART cells were utilized [52,116]. Undoubtedly, the immunosuppressive TME may be a noteworthy obstacle to NB assenting T cell treatment. As we get closer to a customized pharmaceutical age, the utilization of combinatorial restorative stages to overcome tumor heterogeneity shows up to be the way better choice for cancer treatment [59,104]. Combining multimodal regimens to make strides and draw out the anticancer adequacy of receptive exchange treatment whereas at the same time focusing on tumor-associated stroma to overcome tumor elude instruments is directly the center of investigate [11,51]. The ideal anticancer reaction involves the CAR T cell transferring and concentration onto the tumor site [5,21]. To overcome destitute cell trafficking within the TME, an assortment of strategies have been utilized, counting localized conveyance of CAR T units & the transgenic expression of the chemokine receptors on the effector cells. In a metastatic neuroblastoma, assenting exchange of natural killer cells designed to specific interleukin 15 secured natural killer cells since the impact of inhibition of the hypoxia and expanded antitumor movement. CCR2b transgenic expression on CAR T cells significantly increments both in vitro and in vivo chemotaxis in reaction to CCL2 produced by NB cells, and expanded transient capacity is additionally connected to made strides antitumor viability [11,59].

1.4. Scope of mRNA vaccines in neuroblastoma immunotherapy

mRNA immunizations have developed as a potential cancer treatment stage. mRNA immunizations, whether exposed or stacked with a carrier, effectively express the antigens of tumor in APCs after immunization, encouraging the antigen presenting cell actuation and the adaptive safe incitement [21,82]. Given its high strength, secure organization, speedy improvement potential, and cost-effective generation, the mRNA cancer immunization beats other conventional inoculation stages [11,104].



Fig. 1. The immunotherapeutic strategies of neuroblastoma.

Steadiness, inborn immunogenicity, and destitute in vivo transport have all confined the utilize of mRNA antibodies [82,117]. To address these challenges, analysts have looked at fitting mRNA auxiliary changes (e.g. optimization of the codons, alterations of the nucleotide, the mRNAs which are self-amplifying etc.) & detailing procedures (e.g., LPs: lipid nanoparticles, the polymers, & the peptides, etc.) [24,68]. Tuning the organization strategies and combining a few of the mRNA based vaccines with additional drugs which are immunotherapeutic (e.g., checkpoint inhibitors) has promoted the chance of cancer cell end [94,109].

The earliest proof of the safe neuroblastoma systemic intelligence originated from the in vitro investigation that illustrated WBCs from the patients were seen to be toxic for the cells in the tumor cells, as well as tumor evaluations that uncovered safe framework cell invasion [12,53,74]. An assortment of monoclonal antibodies were created in contrast to neuroblastoma cell cultures and utilized to distinguish the cancer related antigens after the presentation of monoclonal counter acting agent (mAb) innovation [10,44,96]. Disialoganglioside (GD2) is the type of antigen that's inexhaustibly created by about all neuroblastoma cells, making it a promising target for both tumor cell discovery and mAb treatment [116,118,119]. CTLs could precisely recognize and annihilate tumor cells as a result of inoculation or hereditary building that blesses them with the antigen receptors which were chimeric, concurring to preclinical ponder utilizing in vitro and transplantable in the tumor sites seen in neuroblastoma [120–122]. Clinical trials based on CTLs, on the other hand, have not continued past pilot and stage I examinations. *Anti*-GD2 mAbs, on the other hand, have experienced critical initial testing and were continued from stage I to stage III clinical trials. In this way, taking after broad cytoreductive chemotherapy, light, and surgery, patients having neuroblastoma which are at high risk are treated with a chimeric *anti*-GD2 monoclonal antibody coupled with interleukin 2 and GM-CSF as was illustrated successful immunotherapy [123–125]. Immunization, assenting cell treatment, and monoclonal counter acting agent (mAb) strategies are the center of continuous preclinical and clinical inquire about [5,7,90]. In neuroblastoma, the tumor microenvironment has as of late been illustrated to be able to suppress the immune response & development advancing tumors and strategies to neutralize this are being investigated to move forward immunotherapy against the neuroblastoma tumors [18,74,75]. Table 1 summarizes the cancer immunotherapy applications of mRNA.

2. Immunotherapy strategies for neuroblastoma

Specificity, affiliation in oncogenesis, expression level, and immunotherapeutic targetability are all characteristics of an awesome tumor antigen. immunogenicity, in show disdain toward of the truth that none of the as of presently open all of the prerequisites are met by centered on antigens [28,56]. When it comes to adults, the finding of neoantigens connected to changes has enormously expanded the number of antigens accessible [4,9,54]. It might maybe be put into use in immunotherapy most pediatric cancers, counting NB, are classified as, have a part less hereditary transformations, which implies they're less likely to urge debilitated, a neoantigen-targeting approach [26,59]. Immunotherapy for pediatric cancers, the lion's share of the inquire about has been centered on concentrating on non-mutated antigens with a distinction in expression between cancerous and non-cancerous cells that are typical [4,54]. The regulation of MHC-1 in cancer cells is getting to be a subject of uncommon intrigued as cellular immunotherapy for neuroblastoma gets pace. MHC-1 levels in neuroblastoma tumors are for the most part very moo, particularly in patients with a tall hazard of the malady [11,43,55]. Whereas diminished MHC-1 expression in cancer is anticipated, new information recommends that the elemental etiology of neuroblastoma may be related to its embryonic beginning. It is therefore imperative to have distant better; a much better; a higher; a stronger; an improved">a stronger information of MHC-1 control amid embryonic neuroblastoma

Table 1
Cancer immunotherapy applications of mRNA.

SL No.	Phase	Method	mRNA encoding	Applications	References
1.	Preclinical	Injection of ex vivo altered T lymphocytes	• CAR-HER2/neo • CAR-CD19 • CAR-mesothelin	• ovarian cancer • lymphoma • leukemia • mesothelioma	[126,127]
		Injection of ex vivo altered dendritic cells	• MUC1 • Surviving • iLRP236	• hematological malignancies	[128,129]
		mRNA injected directly	• CEA4 • NY-ESO • gp100 • TRP2 • Tyrosinase • PSA • STEAP	• melanoma • prostate cancer	[101,113]
2.	Clinical	Injection of ex vivo altered T lymphocytes	CAR containing mesothelin-targeted antibody	• mesothelioma	[92,112]
		Injection of ex vivo altered dendritic cells	• PSA12 • Telomerase • CEA • TriMix • MAGEA • MAGEC • gp 100 • tyrosinase	• prostate cancer • pancreatic cancer • metastatic malignancies • colon cancer • melanoma • leukemia	[5,25]
		mRNA injected directly	• melan-A • tyrosinase • gp 100 • MAGEA 1 • MAGEA 3 • Surviving • MUC 1 • CEA • HER • telomerase • MAGEA 1 • Surviving	• melanoma • renal cell • carcinoma	[10,13,117]

improvement since it may recognize modern helpful targets [25,103,113].

Made strides understanding of tumor cell-immune intuitive, as well as exploiting the anti tumor cell resilient reactions whereas lessening or hindering the pro-tumor and immunosuppressive resilient reactions, will be utilized to create modern and more compelling immunotherapy techniques for treating negligible remaining malady and conceivably clinically quantifiable illness [34,111].

A stage III randomized trial appeared that the advancement and execution of clinical immunotherapy utilizing mAb ch14.18 was effective [47,91,112]. Anti-neuroblastoma T cell treatment tests, such as those examining immunizations and receptive cell treatment, are still within the early stages of investigate and have however to appear that they are compelling [16,82,107]. Pro-tumor resistant framework exercises (Yang) within the microenvironment of the tumor & the hindering influence on the immunotherapy of neuroblastoma are as it were presently being found, and future immunotherapy enhancements will ought to address the tumor microenvironment [22,66]. Table 2 summarizes the hallmarks, drug targets and potential therapeutics for the potential treatment of high risk neuroblastoma.

2.1. Targeting the tumor microenvironment

In neuroblastoma, the regulatory cascades PTEN/PI3K/AKT and RAF/MEK/ERK govern MYCN stability which proves to be as critical determinants for the uncontrollable growth of the tumor tissues, process of angiogenesis, the mode of invasion, the mechanism of apoptosis, and the mechanism of cellular metabolism [14,35]. The PI3K/AKT communication alliance panels the GSK3 dependent modulation of the MYCN and the steadiness of HIF1, therefore the usefulness of the inhibitor molecules attacking those cascades of the signaling process has been tested in neuroblastoma forms [101,106]. According to the findings, people diagnosed at the age of eighteen months had elevated expression of the genes related to inflammation (IL10, IL6R, CD16, CD33, and FCGR3) than those detected at the age of eighteen months. TAMs correspondingly activate hypoxia inducible factor, which helps to promote the hypoxic microenvironment in NB (HIF 2) transcription [19,33]. The immunosuppressive microenvironment in neuroblastoma is created for a variety of reasons, including (1) penetrating immunosuppressive resistant cells like macrophages, administrative T lymphocytes, and the myeloid determined silencer cells, (2) dissolvable components released in the neuroblastoma microenvironment that interfere with immunosuppression, such as TGF β, the interleukin 10, and galectin 1, and (3) vacates in antigen [18,108]. Monoclonal antibodies that attack GD2, a ganglioside existing solely inside the normal neuroblastoma cancer tissues, have demonstrated promising results in patients having neuroblastoma [38,53]. Numerous clinical trials by means of anti GD2 monoclonal antibodies from mice otherwise recombinant anti GD2 monoclonal antibodies, also unaccompanied or in grouping with interleukin 2, the GMCSF, & the retinoic acid, are currently ongoing [12,88]. In a clinical trial for degenerated or intractable neuroblastoma (NCT03209869), the ex vivo generated & stimulated donor NK cells through Hu14.18-IL2 are also being investigated [6,32,44]. T cells with an *anti*-GD2 chimeric antigen receptor (CAR) were recently genetically produced and tested in clinical trials [15,31,83]. Despite CAR T cells' clinical success regarding the hematological malignancies, their usefulness in tumor tissues, as well as the neuroblastoma owing to suppression of the immune response at the tumor microenvironment in the neuroblastoma, has not shown any significant benefit [1,8,79]. As a result, better access to the tumor micro environment of neuroblastoma is important aimed at finding successful treatment strategies for this childhood cancer [21,76,78].

2.2. Targeting infiltrating immune cells

The interaction between cancerous cells and the have safe framework

Table 2
The hallmarks, drug targets and potential therapeutics of high-risk neuroblastoma.

Hallmarks of NB	Drug Targets	Potential Therapeutic	Status	References
1. Signaling of proliferation process	26 S proteasome	Bortezomib	Phase I	[150,151]
	AKT	MK2206 and perifosine	Phase I	[130,131]
	ALK	Crizotinib	Phase Ii	[133,134]
	Aurora kinase A	MLN8237	Phase I	[135,152]
	CDK4 and CDK6	LEE011	Phase I	[153,154]
	IGF1 and IGF2	MEDI-573 and m708.5	Preclinical	[155]
	IGF1R	MAb (R1507 and IMC-A12)	Phase I	[156]
	MYCN	BET domain inhibitor	Preclinical	[157,158]
	PI3K–mTOR	Rapamycin	Phase I	[159,160]
	TRKA and TRKB	Lestaurtinib	Phase I	[161,162]
11. The escaping of growth suppression	BCL-2	ABT-737	Preclinical	[126,163]
	BMI1	Vorinostat	Phase I	[164,165]
	MDM2–p53	Nutlin	Preclinical	[166–168]
14. Avoiding the death of cells	Methylation (CASP8, RASSF1A, DCR1, DCR2, DR4 and DR5)	Decitabine	Phase I	[137,138]
	HDAC	Vorinostat	Phase I	[116,118]
16. Enabling replicative	ATRX (ALT)	ATRX (ALT)	Preclinical	[115,119,122,148]
17. immortality	Telomerase	Imetelstat	Phase I	[112,113]
19. Genome instability	ATRX (ALT), MYCN and telomerase	–	–	[95,97]
20. Metastatic invasion activation	HGF–MET	Crizotinib	Phase I	[106,109]
	TWIST1 (EMT)	Vorinostat	Phase I	[5,25]
	MMP2 and MMP9	AZD1236	Preclinical	[10,16]
	RHO–RAC	Y27632	Preclinical	[83,85]
24. Inducing angiogenesis	VEGF, HIF1α and HIF2α	MAb (bevacizumab)	Phase Ii	[75,76]
25. Tumor-promoting	TAMs	IL-15 (NKT)	Preclinical	[53,59]
26. inflammation				
27. Energy metabolism	GLUT1	3-bromopyruvate	Preclinical	[45,47,72]
28. Evasion of immune	T cells	CAR (14G2a, 5F11, hu3F8 and CE7)	Preclinical/ Phase I	[68,86,87]
29. destruction		MAb (bispecific 3F8 or bispecific hu3F8)	Preclinical	[64,71]
	NK cells, NKT cells and T cells	IL-15	Preclinical	[61,62]
		IL-2	Phase I/Ii/ Iii	[36,37]
	NK cells and granulocytes	MAb (ch14.18, 3F8, hu14.18-K322A and hu3F8)	Phase I/Ii/ Iii	[27,32,38]
	KIR	MAb (*anti*-KIR2DL1, KIR2DL2 and KIR2DL3)	Preclinical	[65,66,70]
	HLA	IFNγ	Phase I	[35,36,63]
	Granulocytes, macrophages	GM-CSF	Phase I/Ii/ Iii	[62]
	B7–H3	MAb (8H9)	Phase I/Ii	[72,87]

decides the rate at which tumors create [41,51,72]. Schreiber et alnotion.'s of "cancer immunoediting" is isolated into three stages: disposal, harmony, and elude [24,68,145]. Both the intrinsic and versatile resistant frameworks collaborate to dispense with the tumor some time recently it gets to be clinically clear amid the early "disposal stage." Within the balance stage, most tumor cells are murdered; be that as it may, certain uncommon mutant cells are not devastated in this stage and move on to the another "equilibrium phase." [120,124,125,146]. Cancerous cells are held in reserve in a state of immune mediated torpidity amid the "harmony stage," which can hold on for the rest of a person's life. The length of the balance stage is decided by the steadiness of the cancer cells immunological resilience and the concentrated of endogenous anti-tumor resistance [128,147]. This persistent resistant weight on hereditarily unsteady tumor cells comes about within the era of variation tumor cells that are not recognized by the safe framework and enter the "elude stage," in which tumors develop without immunological limitations and build up an immunosuppressive microenvironment [116,119,148].

2.3. Anti GD2 monoclonal antibodies

Patients with elevated danger from neuroblastoma are presently treated with dosage involving multiple agents strongly acceptance of chemotherapy and the removal of tumor srugically to attain reduction in the tumor volume, concurring to the results of randomized clinical thinks about directed by countrywide and universal involvement of organizations [27,103]. Anti GD2 monoclonal antibodies with the cytokines, external beam radiation, the differentiation medication isotretinoin, and immunotherapy with anti GD2 monoclonal antibodies with cytokines are all possibilities for consolidating remission [34,111,149]. In patients with high-risk neuroblastoma, the incorporation of anti GD2 monoclonal antibodies improved the event free survival (EFS) and ordinary survival (OS). Anti GD2 monoclonal antibodies tie to the penta oligosaccharide at the conclusion of GD2, and their anti-neuroblastoma activity is interceded by means of the antibody dependent cell mediated cytotoxicity (ADCC) and the complement mediated cytotoxicity (CMC) [21,93,112,143]. Fc receptors on the external area of the cell of leucocytes and natural killer cells (FcgRIIA/CD32 and FcRIIIA/CD16A, respectively) are triggered by the tumor bound monoclonal antibodies and discharge cytotoxic granules and cytokines that kill tumor cells. When C1q binds to the Fc of tumor associated monoclonal antibodies, the accompaniment mechanism is triggered, resulting in the formation of membrane occurrence compounds that accompanies the breaching in the neuroblastoma cell surface and lyse the cancerous cells, culminating in CMC [41,51,95]. Non-immune responses such as preservation signal obstruction and anoikic which is an stimulated process of apoptosis where the supporter cells separate from the external environment, might get boosted by monoclonal antibodies [2,3,114]. Table 3 summarizes the clinical trials for the neuroblastoma found on clinicaltrials.gov. Fig. 2 displays the immune reactions on the tumor sites after the application of cancer vaccines.

3. mRNA based cancer vaccines

Cancer vaccine is a long-awaited helpful and preventive immunotherapy approach for inspiring T lymphocyte reactions which are specific to antigens and maybe accomplishing longer medical advantage [169,170]. In any case, in spite of cheerful signals of immunogenicity over most definitions, most CV clinical trials have had destitute comes about within the past [150,171].

Mechanical progressions in antibody conveyance frameworks, immunogenomic profiling procedures, and antigen/epitope determination have all happened within the final decade [151,172]. As a result, early-phase clinical trials have appeared that CVs can create tumor-specific and, in a few circumstances, noteworthy restorative reactions. It's worth noticing that the world-record-breaking speed with which the coronavirus illness (COVID-19) widespread immunization was made was to a great extent based on fabricating foundations and specialized stages as of now in put for CVs [130,173,174]. As a result, inquire about, clinical information, and frameworks put in put in reaction to the SARS-CoV2 plague can offer assistance quicken CV development. mRNA antibodies are a generally modern antibody sort that holds a parcel of potential for long-term. This certainty stems from later ponders that appear the effectiveness of mRNA immunizations in combating an assortment of cancers and irresistible infections when conventional immunization stages may come up short to create defensive safe reactions [131,175]. These discoveries would not have been attainable without later breakthroughs within the zone, such as the creation of secure and compelling materials for in vivo mRNA organization and improved strategies for high-quality mRNA union [133,134]. An modern cancer inoculation approach includes immunizing patients with manufactured mRNA communicating tumor-associated antigens. Researchers explored nasal organization of mRNA immunizations with emphatically stimulating protamine to distillate mRNA, shape a steady polycation mRNA composite, and typify the composite with DOTAP or Chol or DSPE PEG cationic liposomes in arrangement to avoid mRNA debasement [132,176,177], advance the antigen presenting cells insertion, & initiate an reaction involving anti-tumor resistance [135,136,152]. In vitro, cationic liposome/protamine complex (LPC) retention of antibody particles was much higher, as were its capacities to advance dendritic cell development, coming about in a capable anti-tumor safe reaction [178,179]. In an aggressive Lewis lung cancer demonstration, immunization through the nose of mice with cationic LPC carrying mRNA communicating cytokeratin 19 actuated a noteworthy cellular resistant reaction and decreased tumor advancement [153,154].

Effective in vivo messenger RNA dispersion is required to achieve therapeutic importance. Extracellular mRNA essentially gets through the membrane border involving lipids to penetrate the inside of the cell and be converted into a protein complex [180–182]. The physicochemical features of mRNA structural compounds can have a major impact on cellular movement and organ distribution, and cell type appears to influence mRNA absorption mechanisms [183,184]. So far, two main methods for delivering mRNA vaccines have been reported [155,185,186]. To begin with, ex vivo mRNA stacking taken after by the re-introduction of transfected cells58; and moment, coordinate the parent mRNA infusion with or without the involvement of a carrier [156,187,188]. Fig. 3 portrays the development of neoantigen vaccines for specific type of tumor tissues.

3.1. mRNA immunogenicity and paradoxical effects

Pattern recognition receptors in the host immune system initiate the innate immune response by identifying foreign motifs identified by means of pathogen associated molecular patterns (PAMPs) (PRRs) [120,125]. APCs, which are the major target cells for mRNA cancer immunotherapy, have a lot of these receptors [124,204]. Since it is known by an assortment of cell exterior, the endosome, and the cytosolic PRRs, exogenous IVT messenger RNA is inherently immunostimulatory [116,123]. Toll-like receptors (TLR)-7 and 8 (one kind of PRR) detect IVT mRNA within the endosomal membrane, which stimulates the MyD88 pathway, which subsequently stimulates Type-1 interferon (IFN) pathways and secretes inflammatory cytokines [118,119,121]. Other PRR families detect foreign mRNAs in the cytosol, together with retinoic acid inducible gene-I-like (RIG-I-like) receptors, oligoadenylate synthetase (OAS) receptors, and RNA-dependent protein kinase receptors (PKR) [122,148]. These PRRs could be able to detect a variety of RNAs, notably dsRNA and single-stranded RNA (ssRNA), and block mRNA translation, as mentioned previously [115,144,147].

Numerous PRR enactment and sort I IFN generation can be both profitable and destructive to anti-cancer treatment [101,112,113]. Enactment of sort I IFN pathways invigorates APC actuation and development, improves antigen introduction, and inspires effective versatile

Table 3
Clinical trials for the neuroblastoma vaccines.

SL No.	Clinical trials identifier	Title	Status	Interventions	Conditions	Year	Sponsor	Location
1.	NCT00048386	Neuroblastoma vaccine for treatment of high-risk neuroblastoma after chemotherapy (cyche2)	Completed	biological: autologous neuroblastoma vaccine	Neuroblastoma	2002	Malcolm Brenner	Texas, USA
2.	NCT00911560	Bivalent vaccine with escalating doses of the immunological adjuvant opt-821, in combination through oral β-glucan for high-risk neuroblastoma	Active, not recruiting	• biological: adjuvant opt-821 in a vaccine containing two antigens (gd2l and gd3l) covalently linked to klh • biological: oral β-glucan	Neuroblastoma	2009	Memorial Sloan Kettering Cancer Center	New York, USA
3.	NCT04936529	A study of a vaccine in combination with β-glucan and gm-csf in people with neuroblastoma	Recruiting	• dietary supplement: β-glucan • drug: gm-csf • biological: opt-821	Neuroblastoma	2021	Memorial Sloan Kettering Cancer Center	New York, USA
4.	NCT04049864	Dna vaccination against neuroblastoma	Recruiting	• biological: dna vaccine • biological: salmonella oral vaccine • drug: lenalidomide	Relapsed Neuroblastoma	2019	Belarusian Research Center for Pediatric Oncology, Hematology and Immunology	Minsk Region, Belarus
5.	NCT00101309	Vaccine therapy and interleukin-2 in treating young patients with relapsed or refractory ewing's sarcoma or neuroblastoma	Active, not recruiting	• living: aldesleukin • living: autologous ebv-transformed b lymphoblastoid-tumor fusion cell vaccine • biological: therapeutic autologous lymphocytes	• Neuroblastoma • Sarcoma	2005	Milton S. Hershey Medical Center	Pennsylvania, USA
6.	NCT01192555	Allogeneic tumor cell vaccination with oral metronomic cytoxan in patients with high-risk neuroblastoma (atomic)	Active, not recruiting	• biological: neuroblastoma vaccine (unmodified sknlp, with gene-modified sjnb-jf-il2 and sjnb-jf-ltn neuroblastoma cells • drug: cytoxan	Neuroblastoma	2010	Baylor College of Medicine	Texas, USA
7.	NCT00703222	A phase i/ii study of immunization with lymphotactin and interleukin 2 gene modified neuroblastoma tumor cells (chesat)	Active, not recruiting	• biological: snjb-jf-il2 and sjnb-jf-lptn + dose level 1 sknlp • biological: snjb-jf-il2 and sjnb-jf-lptn + dose level 2 sknlp	Neuroblastoma	2008	Baylor College of Medicine	Texas, USA
8.	NCT01241162	Decitabine followed by a cancer antigen vaccine for patients with neuroblastoma and sarcoma	Completed	• biological: autologous dendritic cell vaccine with adjuvant	• Neuroblastoma • Ewings Sarcoma • Osteogenic Sarcoma • Rhabdomyosarcoma • Synovial Sarcoma	2010	University of Louisville	Kentucky, USA
9.	NCT00944580	A vaccine study for high risk cancers	Withdrawn	• biological: mage-a1, mage-a3, and ny-eso-1 vaccine	• Neuroblastoma • Rhabdomyosarcoma • Osteogenic Sarcoma	2009	Penn State University	USA
10	NCT00405327	A pilot investigation of tumor cell vaccine for high-risk solid tumor patients following stem cell transplantation	Completed	• biological: tumor lysate-pulsed dendritic cell (dc) vaccine • other: hematopoietic stem cell transplantation (hsct)	• Sarcoma • Neuroblastoma • Wilm's Tumor	2006	University of Michigan Rogel Cancer Center	Michigan, USA
11	NCT04239040	Gvax plus checkpoint blockade in neuroblastoma	Recruiting	• procedure: tissue collection • biological: gvax vaccine • drug: nivolumab • drug: ipilimumab	• Neuroblastoma • Pediatric Solid Tumor	2020	Dana-Farber Cancer Institute	Massachusetts, USA
12	NCT01953900	Ic9-gd2-car-vzv-ctls/ refractory or metastatic gd2-positive sarcoma and neuroblastoma (vegas)	Active, not recruiting	• genetic: gd2 t cells • biological: vzv vaccine • drug: fludarabine • drug: cyclophosphamide	• Osteosarcoma • Neuroblastoma	2013	Baylor College of Medicine	Texas, USA
13	NCT00923351	Therapy to treat ewing's sarcoma, rhabdomyosarcoma or neuroblastoma	Completed	• drug: tumor purged/ cd25 depleted lymphocytes • biological: tumor purged/cd25 depleted lymphocytes with tumor lysate/klh pulsed dendritic cell vaccine • drug: rhil-7 • biological: tumor lysate/ klh pulsed dendritic cell vaccine	• Neuroblastoma • Sarcoma • Rhabdomyosarcoma-Embryonal • Rhabdomyosarcoma-Alveolar • Neuroectodermal Tumors, Primitive, Peripheral	2009	National Cancer Institute (NCI)	Maryland, USA



Fig. 2. Immune response and effect of cancer vaccines on the tumor tissues.



Fig. 3. Development of the neoantigen cancer vaccines for specific tumor tissues.

resistant reactions, making it possibly advantageous for inoculation [94,103]. Intrinsic immune discovery of RNAs, on the other hand, maybe connected to antigen expression concealment, hosing safe reaction [92,94,97].

The paradoxical impact of Sort I IFN enactment may be seen not as it were in antigen expression but too in CD+ 8 T cell actuation. Sort I IFNs' double impact on $CD8^+$ T cell resistance has been altogether talked about somewhere else [95,108,114]. In rundown, sort I IFNs' stimulatory or inhibitory impacts onto the CD+ 8 T lymphocyte actuation are likely to be affected by the timing and energy of IFNAR and the signaling of TCR, that might have the potential to influence the assistance by the strategies of conveyance of mRNA cancer antibodies [106,109].

3.2. *Self-amplifying mRNA vaccines*

SAM is another RNA immunization innovation that has the potential

to extend the estimate and term of antigen generation [27,29,30]. The auxiliary protein-producing qualities of each alphavirus stayed substituted with qualities programming the antigens of intrigued, but the RNA duplication apparatus has remained unaltered [40,41,205]. The multi-enzyme replicase complex, which drives RNA amplification in the cytoplasm, was formed by preserving the viral RNA dependent RNA polymerase and proteins having no specific structures [42,43,143].

SAMs are able to self-amplify over time due to the viral replication machinery's integrity, resulting in more powerful and long-lasting immune function [39,107,110]. The SAM platforms beats previous non-replicating mRNA vaccine technologies by allowing a significant amount of antigen to be synthesized over a long dated from a short dose immunization [22,91,104].

3.3. Delivery of mRNA cancer vaccines

To remain useful, mRNA must reach the have cytoplasm to precise specific antigens; however, the mRNA atom is as well huge to pass past the cell film through free dissemination [12,19,23]. Moreover, both mRNA and the cell layer are contrarily charged, making mRNA transport more challenging. Moreover, extracellular ribonucleases found within the skin and blood may quickly breakdown mRNA [2,96,100]. As a result, one of the foremost troublesome application issues for mRNA antibodies is getting sufficient mRNA into sufficient cells with satisfactory tall interpretation levels, which requires profoundly particular and compelling mRNA conveyance strategies [20,24].

3.3.1. Lipid nanoparticle-based mRNA delivery system

LNPs, which were initially created to transport siRNAs, are presently being utilized to provide mRNA and are the foremost clinically appropriate non-viral conveyance vehicles [89,98]. An ionizable particle resembling an amino acid, an aide phospholipid, the cholesterol, and the lipid anchored polyethylene glycol make up the lion's share of LNPs (PEG) [1,28,93]. The lipid which could be ionizable is an amphipathic structure having a hydrophilic headgroup encompassing one or more ionizable amines, self-assembly-promoting hydrocarbon chains, and a connector interfacing the headgroups and chains of hydrocarbon [17,90,93].

Ionizable lipids are planned to get positive charges by protonating free amines at moo pH values [5,7,8]. There are two primary reasons: (1) Amid the fabricating prepare of LNP, emphatically charged lipids can connected through electrostatic intuitive Advance the embodiment of adversely charged mRNA; (2) The microenvironment which becomes acidic endosomal in structure after intracellular conveyance of lipid nanoparticles, emphatically charged lipids can associated with the ionic endosome film to advance film combination and destabilization, driving to LNPs And endosome discharge mRNA [22,39,110].

3.3.2. Polymer dependent delivery system for mRNA

The polyamines, the dendrimers, and co polymers which are biodegradable are a few of the foremost broadly utilized polymer-based compounds for mRNA corruption [1,24]. When compared to manufactured LNPs, polymer-based conveyance frameworks have minor immaculateness owing to tall poly dispersity, lesser removal rate due to expansive atomic weight, & decline harmfulness outline owing to reduced charge thickness, and they are not as clinically progressed for mRNA conveyance as lipids which are ionizable [19,99]. Structural alterations, such as the consolidation tails of lipids, hyperbranched bunches, & the biodegradable moieties, have explored to extend the tolerability and solidness of polymeric platforms [177,206].

3.3.3. Peptide dependent delivery system of mRNA

Protamine which is a cationic peptide was utilized in a few early trials to provide mRNA immunizations. Protamine condenses mRNA suddenly by electrostatic contact, avoiding extracellular RNases from debasing the typified mRNA [73,98]. The protamine-mRNA complexes can possibly work as an adjuvant by enacting TLR7/8 and activating a Th-1 resistant reaction [86,89]. Protamine-mRNA compounds by themselves, on the other side, showed poor translation ability, which could be as a result of an abnormally constricted contact among protamine and the mRNA [17,20]. To solve this problem, CureVac AG developed RNActive®, a two-compartment formulation. The researchers united protamine-mRNA complexes (50%) with bare antigen-coding mRNA which was 50%. The protamine complexes are only used as an adjuvant; the antigen is produced by the nucleoside modified mRNA. Few phase I or phase II clinical trials with RNActive® encapsulating TAAs-encoding mRNAs are being conducted for a range of solid tumors. Most RNActive® vaccines are well endured and responded to, and some have showed minor antitumor efficacy [100,207–209].

3.3.4. Injection routes of mRNA cancer vaccines

The foremost common infusion strategies for mRNA cancer immunizations are intramuscular, subcutaneous, and intradermal infusions. Intra muscular infusions of PAMAM loaded OVA mRNA for melanoma treatment in mice, Moderna lipid nanoparticles which were optimized for intra muscular infusion of mRNA antibodies, sub cutaneous infusion of modified peptide DOTAP liposomes, sub cutaneous infusion of lipid nanoparticles with optimized lipid compositions and lipid structures for antitumor immunizations, intradermal infusion of LPR to increase the anti cancer resistance [72,210,211]. Intramuscular infusions are as often as possible favored since of the adaptability of infusion volume, comfort of measurement, and nonattendance of security concerns, with a moo chance of unfavorable reactions at the infusion location [212,213]. Immunization conveyance to the skin, which could be a profoundly immunocompetent locale, has long been thought to be a way to boost immunization reaction [214,215]. Fig. 4 displays the mRNA vaccine delivery strategies and the combination immunotherapy of mRNA nano vaccines.

4. Therapeutic considerations and challenges for mRNA NB vaccines

4.1. GMP production of mRNA vaccines

GMP mRNA generation starts with the creation of DNA layouts, taken after by enzymatic IVT, and takes after the same multistep strategy as inquire about scale union, with extra controls to guarantee the product's security and strength [216,217]. Depending on the circumstances, the method may be changed to some degree based on the mRNA construct and chemistry. altered nucleosides, capping strategies, or layout are all point by point here to suit changed nucleosides, capping methodologies, or format expulsion [218,219]. Template plasmid DNA created in Escherichia coli is utilized to begin the fabricating process [220,221]. To encourage generation of runoff transcripts with a limitation chemical, *E. coli* is linearized. At the 3′ conclusion, there's a poly(A) tract. Taking after that, a DNA dependent RNA polymerase collected from bacteriophage synthesizes mRNA from NTPs (like T7, SP6, or T3) [222–224]. After that, DNase is utilized to breakdown the format DNA. At long last, the mRNA is capped, either chemically or enzymatically, to permit for viable interpretation in vivo [13,225,226].

After mRNA is delivered, it experiences an arrangement of refinement forms to dispose of response components such as proteins, unbound nucleotides, remaining DNA, & condensed RNA parts. Whereas the precipitation of LiCl is commonly utilized for laboratory-scale arrangement, derivatized micro beads inside the clump or column shapes, that are simpler to handle on an expansive scale, are utilized for clinical refinement [53,227]. The evacuation of dsRNA and other contaminants from certain mRNA stages is vital for the ultimate product's efficacy, since it may be a capable inducer of interferon-dependent interpretation restraint [81,228,229]. At the research facility scale, reverse-phase FPLC was utilized to do this, and adaptable fluid decontamination strategies are being considered. After refinement, the mRNA is exchanged to a last



Fig. 4. mRNA vaccine delivery mechanisms and combination immunotherapy of mRNA Nano vaccines.

capacity buffer and sterile-filtered some time recently being filled into vials for clinical utilization [214,230]. Both enzymatic and chemical degradation components are able of debasing RNA. Definition buffers are checked for sullying RNA ase and may incorporate buffer components such as cancer stoppage mediators and chelators, that helps to decrease the influences of accessible oxygen types and divalent metal units that results in mRNA insecurity [24,226,231].

The formulation of mRNAs may be a hot theme presently. In spite of the reality that most items for early phase trials are solidified (70 °C), endeavors to make definitions that are steady at increased temperatures and so more fitting for immunization dissemination are continuous [1, 81,232]. Concurring to distributed reports, steady refrigerated or room temperature details are conceivable. Subsequently lyophilization & volume at 5–25 °C for 3 an extended period and at 40 °C for half a year, the RNActive stage was appeared to be useful [19,207,233]. Another study found that beneath refrigerated circumstances, freeze-dried bare mRNA remains solid for at slightest 10 months [93,94,98]. Bundling mRNA items in nanoparticles or co-formulation with RNase inhibitors may offer assistance increment their steadiness.

4.2. Regulatory aspects of NB mRNA vaccines

The FDA and the European Medications Agency (EMA) have issued no specific counsel for mRNA immunization arrangements [17,95,234]. Be that as it may, the developing number of clinical considers done beneath EMA and FDA supervision shows that specialists have acknowledged differing organizations' ways to illustrating that merchandise are secure and suitable for testing in individuals [76,235,236]. Numerous of the directing standards that have been laid out for DNA vaccines162 and quality treatment vectors163,164 may likely be connected to mRNA with a few alterations to reflect the particular properties of mRNA since it comes into the wide inoculation category of hereditary immunogens [92, 237,238]. Hinz and colleagues emphasize the different administrative courses commanded for preventive irresistible malady vs restorative employments in an exhaustive examination of EMA rules for RNA antibodies [97,239]. In any case of how existing suggestions are classified, there are certain common components in what is said in these papers and what has been detailed for recently distributed clinical trials [240,241]. Preclinical and clinical comes about showing biodistribution and solidness in mice, sickness assurance in a significant creature show (ferrets), and immunogenicity, nearby reactogenicity, and harmfulness in people were highlighted in a later think about on an mRNA antibody against flu infection [242,243]. As mRNA vaccines gotten to be progressively common within the inoculation industry, uncommon counsel will likely be produced to diagram the requirements for creating and testing novel mRNA antibodies [25,100,244].

4.3. Safety of mRNA vaccines

Since inoculations are given to sound individuals, the model for security in modern preventive antibodies is very strict [86,245]. mRNA amalgamation maintains a strategic distance as of the consistent risks associated with other inoculation points, such as live contamination, vectors involving virus, disabled contagion, and sub unit protein immunizations, since it does not require dangerous chemicals or cell societies that will be sullied by adventitious infections [47,215]. Besides, since mRNA is made rapidly, there are constrained conceivable outcomes for contaminating organisms to enter [22,72]. The putative risks of disease or vector incorporation into the DNA of the cell which are not a concern for mRNA in inoculated people. For the reasons expressed over, mRNA antibodies are thought to be a for the most part secure inoculation definition [47,82].

A few particular mRNA immunizations have presently been tried in clinical trials extending from stage I to stage IIb and have been found to be secure and well endured. Later human thinks about, on the other hand, have appeared mellow to extreme infusion location or systemic reactions for a few mRNA frameworks [28,53,55]. Neighborhood and systemic aggravation, bio-distribution and perseverance of the communicated immunogen, incitement of antibodies that are autoreactive, and probable damaging effects of any foreign nucleotides and conveyance framework components are all potential security concerns that will likely be explored in future preclinical and clinical ponders [12,83,114]. A few mRNA-based immunization frameworks can be a source of concern [40, 51,177].

5. Discussion

Cancer immunotherapy will upgrade long-term patient survival whereas diminishing genotoxic therapy-related intense and persistent toxicities. Immunotherapy has changed the common history of high-risk NB from an all-around lethal sickness to a conceivably treatable malady in more than half of patients, making it one of the uncommon malignancies that have been changed by immunotherapy. Be that as it may, we still got to learn more about the biological pathways and mechanisms of neuroblastoma & the anti GD2 treatment, which can have suggestions for future therapeutics involving the use of antibodies in the neuroblastoma and immunotherapy of tumor is common. Novel counter-acting agent shapes possesses the ability to provide radiation at high doses to create reactions without inflicting toxicological response in the long run, giving solid options to chemotherapy which are strictly regulated and have precise dosing thought is required to treat the neuroblastoma that poses massive risk to the children, which is considered to be much obliged to breakthroughs in protein building. The combination of Fc dependent and T lymphocyte mediated counter acting agent tactics, as well as high TI antibody targeting strategies, may offer assistance to children with metastatic neuroblastoma.

The treatment of neuroblastoma has seen a few advances much obliged to progressed early determination and the utilize of immunotherapy. Unituxin, a chimeric GD2-specific counter acting agent, has appeared to make strides endurance rates in patients and thus lowering mortality rates experiencing ordinary multiple modes of treatment, and it is rapidly getting to be a schedule component of the high risk neuroblastoma treatment. One of the foremost critical highlights of this technique involving the immunotherapy is that it has no prolonged or total harmfulness, which is particularly pivotal for the body of a kid. At the same time, immunotherapy utilizing GD2-specific antibodies isn't ideal since it encompasses a part of side impacts, most of which are related to on-target/off-tumor harmfulness. The larger part of Unituxin patients (85%) have extreme torment that can as it were be diminished with solid analgesics. Pyrexia, hypotension, and capillary spill disorder are all commonplace unfavorable impacts of this sedate. As a result, effective high risk neuroblastoma immunotherapeutic approach involves the enhancement of prevailing strategies as well as the creation of modern ones.

RNA vaccines are engaging as cancer immunotherapy since they permit for the conveyance of expansive sums of patient-specific antigens determined from a little tumor test, are not HLA-restricted, initiate humoral and cellular safe reactions, give costimulatory signals, are non-oncogenic, and are well-tolerated. A few approaches have been created to extend IVT mRNA solidness and translational effectiveness, as well as to optimize RNA immunization organization, as point by point in this consider. In spite of these improvements, clinical reactions to RNA immunizations are still restricted.

mRNA immunizations are presently seeing a surge in principal and clinical advancement. Hundreds of preclinical and clinical papers illustrating the adequacy of these stages have been distributed within the final two a long time alone. Whereas most early investigations on mRNA antibodies positioned on the specific cancer types, a number of ensuing ponders have demonstrated the viability and adaptability of the mRNA to ensure in contradiction of a wide extension of irresistible infections, counting flu infection, Ebola infection, Zika infection, Streptococcus spp., and T. gondii. The foremost groundbreaking of all was the advancement

of mRNA-based COVID-19 antibodies. With the later authorizing of two mRNA LNP immunizations to avoid COVID-19, preclinical and clinical inquire about mRNA antibodies is detonating in both cancer and irresistible malady segments. The contrasts between making cancer vaccines and irresistible ailment immunizations stem from the truth that most irresistible illness immunizations are preventative, though cancer immunizations are helpful. As it were two FDA-approved preventative cancer immunizations exist, and these two immunizations are utilized to avoid the cancers that are induced by virus (HPV and HBV). In spite of the reality that anti-cancer preventive antibodies are still within the preclinical arrange of improvement, clinical interpretation is hampered by antigen expectation issues and destitute immunogenicity. Moment, most antigens for irresistible ailment (bacterial or viral) are exogenous themes that the MHCII particle by and large presents. Immunizations that target these remote antigens cause a humoral reaction intervened by neutralizing antibodies. The immune reaction intervened by $CD4^+$ T cells is to some degree included and vital in a few circumstances, but $CD8^+$ cytotoxic T cells are basic within the clearance of dangerous cells with physical modifications. In this way, the anticancer restorative immunization must not as it was upgrade humoral and $CD4^+$ T cell reactions, but too actuate the MHCI-mediated CD+ 8 T cell reactions, advance complicating the errand of viably upgrading antitumor resistance. Another key bumbling piece to creating viable anticancer antibodies is distinguishing and viably conveying profoundly immunogenic tumor-specific antigens. Tumor antigens shift a parcel from individual to individual, and a few are less immunogenic than others, making it troublesome for the have resistant framework to recognize them. Indeed, in case the antigen is capable of stimulating an immune response thus being immunogenic, a suppressive microenvironment can avoid effective T cells from invading and debilitate T cells. At last, as a restorative immunization for treating an incessant condition such as cancer, multiple/repeatable dosing at bigger dosages than preventive immunizations is required, raising the security prerequisites for both mRNAs and carriers.

In spite of the reality that finding immunogenic TAAs or the TSAs and incapacitating the suppressive microenvironment of the tumor sites stay key challenges for the mRNA antibodies, the later disclosure and distinguishing proof of neoantigens has encouraged customized inoculation treatment applications. Within the customized inoculation campaign, mRNA encoded neoantigens have developed as the pioneer. Personalized inoculations have as of now appeared empowering results (with a readout of antitumor insusceptibility) in various clinical trials treating an assortment of strong tumors, counting metastatic melanoma and extreme pancreatic malignancies, introducing in a modern period for restorative cancer immunizations.

6. Conclusion

In a nutshell, mRNA could be an adaptable and powerful cancer antibody stage. Its advance toward clinical interpretation will essentially progress our capacity to fight neuroblastoma. Future investigate ought to proceed to center on (but not constrained to) understanding and utilizing mRNA's confusing inalienable natural resistance, progressing antigen expression and introduction effectiveness through the advancement of progressed and acceptable transport frameworks, and adjusting the structures of mRNA to attain amplified & controlled term of expression. Coordinate comparisons of mRNA expression stages ought to uncover which stages are best for detached and dynamic immunization. Given the tremendous number of potential mRNA stages, more head-to-head comparisons would be greatly advantageous to the immunization industry, permitting analysts to center their assets on the stages that are most suited for each application. In neuroblastoma, point by point, evidence-based chance stratification has permitted for the acceleration of treatment for high-risk people whereas lessening treatment for low-risk patients. As a result, in general, results have moved forward, but more work is required to preserve this victory.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] M.A. Islam, J. Rice, E. Reesor, H. Zope, W. Tao, M. Lim, J. Ding, Y. Chen, D. Aduluso, B.R. Zetter, O.C. Farokhzad, J. Shi, Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice, Biomaterials 266 (2021) 120431, https://doi.org/10.1016/j.biomaterials.2020.120431.

[2] Z. Jahanafrooz, B. Baradaran, J. Mosafer, M. Hashemzaei, T. Rezaei, A. Mokhtarzadeh, M.R. Hamblin, Comparison of DNA and mRNA vaccines against cancer, Drug Discov. Today 25 (2020) 552–560, https://doi.org/10.1016/j.drudis.2019.12.003.

[3] S. Liu, Q. Jiang, X. Zhao, R. Zhao, Y. Wang, Y. Wang, J. Liu, Y. Shang, S. Zhao, T. Wu, Y. Zhang, G. Nie, B. Ding, A DNA nanodevice-based vaccine for cancer immunotherapy, Nat. Mater. 20 (2021) 421–430, https://doi.org/10.1038/s41563-020-0793-6.

[4] J.A. Myers, J.S. Miller, Exploring the NK cell platform for cancer immunotherapy, Nat. Rev. Clin. Oncol. 18 (2021) 85–100, https://doi.org/10.1038/s41571-020-0426-7.

[5] T. Vanichapol, S. Chutipongtanate, U. Anurathapan, S. Hongeng, Immune escape mechanisms and future prospects for immunotherapy in neuroblastoma, BioMed Res. Int. 2018 (2018), https://doi.org/10.1155/2018/1812535.

[6] Y. Wang, M. Wang, H.X. Wu, R.H. Xu, Advancing to the era of cancer immunotherapy, Cancer Commun. (2021) 803–829, https://doi.org/10.1002/cac2.12178.

[7] S. Joshi, Targeting the tumor microenvironment in neuroblastoma: recent advances and future directions, Cancers 12 (2020) 1–22, https://doi.org/10.3390/cancers12082057.

[8] C.L. Szanto, A.M. Cornel, S.V. Vijver, S. Nierkens, Monitoring immune responses in neuroblastoma patients during therapy, Cancers 12 (2020) 1–20, https://doi.org/10.3390/cancers12020519.

[9] N. Gong, N.C. Sheppard, M.M. Billingsley, C.H. June, M.J. Mitchell, Nanomaterials for T-cell cancer immunotherapy, Nat. Nanotechnol. 16 (2021) 25–36, https://doi.org/10.1038/s41565-020-00822-y.

[10] N.K.V. Cheung, M.A. Dyer, Neuroblastoma: developmental biology, cancer genomics and immunotherapy, Nat. Rev. Cancer 13 (2013) 397–411, https://doi.org/10.1038/nrc3526.

[11] F. Marofi, O.F. Abdul-Rasheed, H.S. Rahman, H.S. Budi, A.T. Jalil, A.V. Yumashev, A. Hassanzadeh, M. Yazdanifar, R. Motavalli, M.S. Chartrand, M. Ahmadi, A. Cid-Arreguid, M. Jarahian, CAR-NK cell in cancer immunotherapy; A promising frontier, Cancer Sci. 112 (2021) 3427–3436, https://doi.org/10.1111/cas.14993.

[12] P. Jabbari, S. Hanaei, N. Rezaei, State of the art in immunotherapy of neuroblastoma, Immunotherapy 11 (2019) 831–850, https://doi.org/10.2217/imt-2019-0018.

[13] J.M. Abramo, A. Reynolds, G.T. Crisp, M. Weurlander, M. Söderberg, M. Scheja, H. Hult, A. Wernerson, A. Emacs, U.E. Distribution, W. Makes, A. Like, O. Text, O. T, T.A. Interface, D.C. Sets, T.R. Look, E. Veterans, K. Bindings, C. Aquamacs, T.E.X. Support, T.E.X. Previewer, C. Beaumont, M. O'Doherty, L. Shannon, D. Baume, M.Y. *, M. Coffey, A. Bhatara, P. Laukka, D.J. Levitin, A.-A. Darrow, W. Hornby, B. Gingras, I. Symposium, P.S. Isbn, T. Author, a E.C. All, A. Majid, L. Boroditsky, A. Gaby, M. Petre, G. Rugg, Individuality in music performance, Assess Eval. High Educ. 37 (2012) 435, https://doi.org/10.1007/82.

[14] J.A. Park, N.K.V. Cheung, Targets and antibody formats for immunotherapy of neuroblastoma, J. Clin. Oncol. 38 (2020) 1836–1848, https://doi.org/10.1200/JCO.19.01410.

[15] S. Modak, N.K.V. Cheung, Disialoganglioside directed immunotherapy of neuroblastoma, Cancer Invest. 25 (2007) 67–77, https://doi.org/10.1080/07357900601130763.

[16] A. Heczey, C.U. Louis, Advances in chimeric antigen receptor immunotherapy for neuroblastoma, Discov. Med. 16 (2013) 287–294.

[17] N. Pardi, M.J. Hogan, F.W. Porter, D. Weissman, mRNA vaccines-a new era in vaccinology, Nat. Rev. Drug Discov. 17 (2018) 261–279, https://doi.org/10.1038/nrd.2017.243.

[18] B.J. Poelaert, S. Romanova, S.M. Knoche, M.T. Olson, B.H. Sliker, K. Smits, B.L. Dickey, A.E.J. Moffitt-Holida, B.T. Goetz, N. Khan, L. Smith, H. Band, A.M. Mohs, D.W. Coulter, T.K. Bronich, J.C. Solheim, Nanoformulation of CCL21 greatly increases its effectiveness as an immunotherapy for neuroblastoma, J. Contr. Release 327 (2020) 266–283, https://doi.org/10.1016/j.jconrel.2020.07.024.

[19] L. Miao, Y. Zhang, L. Huang, mRNA vaccine for cancer immunotherapy, Mol. Cancer 20 (2021) 1–23, https://doi.org/10.1186/s12943-021-01335-5.

[20] J.D. Beck, D. Reidenbach, N. Salomon, U. Sahin, Ö. Türeci, M. Vormehr, L.M. Kranz, mRNA therapeutics in cancer immunotherapy, Mol. Cancer 20 (2021) 1–24, https://doi.org/10.1186/s12943-021-01348-0.
[21] E.R. Webb, S. Lanati, C. Wareham, A. Easton, S.N. Dunn, T. Inzhelevskaya, F.M. Sadler, S. James, M. Ashton-Key, M.S. Cragg, S.A. Beers, J.C. Gray, Immune characterization of pre-clinical murine models of neuroblastoma, Sci. Rep. 10 (2020) 1–17, https://doi.org/10.1038/s41598-020-73695-9.
[22] R.C. Seeger, Immunology and immunotherapy of neuroblastoma, Semin. Cancer Biol. 21 (2011) 229–237, https://doi.org/10.1016/j.semcancer.2011.09.012.
[23] F. Morandi, F. Sabatini, M. Podestà, I. Airoldi, Immunotherapeutic strategies for neuroblastoma: present, past and future, Vaccines 9 (2021) 1–23, https://doi.org/10.3390/vaccines9010043.
[24] F. Kowalzik, D. Schreiner, C. Jensen, D. Teschner, S. Gehring, F. Zepp, mRNA-Based Vaccines (2021) 1–15.
[25] Y. Yin, X. Li, H. Ma, J. Zhang, D. Yu, R. Zhao, S. Yu, G. Nie, H. Wang, In situ transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy, Nano Lett. 21 (2021) 2224–2231, https://doi.org/10.1021/acs.nanolett.0c05039.
[26] K. Tarte, B. Klein, Dendritic cell-based vaccine: a promising approach for cancer immunotherapy, Leukemia 13 (1999) 653–663, https://doi.org/10.1038/sj.leu.2401394.
[27] O.J. Finn, The dawn of vaccines for cancer prevention, Nat. Rev. Immunol. 18 (2018) 183–194, https://doi.org/10.1038/nri.2017.140.
[28] D. Karan, J.M. Holzbeierlein, P. Van Veldhuizen, J.B. Thrasher, Cancer immunotherapy: a paradigm shift for prostate cancer treatment, Nat. Rev. Urol. 9 (2012) 376–385, https://doi.org/10.1038/nrurol.2012.106.
[29] F. Berthold, A. Ernst, B. Hero, T. Klingebiel, B. Kremens, F.H. Schilling, T. Simon, Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation, Br. J. Cancer 119 (2018) 282–290, https://doi.org/10.1038/s41416-018-0169-8.
[30] M. Li, C. Sun, X. Bu, Y. Que, L. Zhang, Y. Zhang, L. Zhang, S. Lu, J. Huang, J. Zhu, J. Wang, F. Sun, Y. Zhang, ISL1 promoted tumorigenesis and EMT via Aurora kinase A-induced activation of PI3K/AKT signaling pathway in neuroblastoma, Cell Death Dis. 12 (2021) 1–13, https://doi.org/10.1038/s41419-021-03894-3.
[31] G. Zhu, G.M. Lynn, O. Jacobson, K. Chen, Y. Liu, H. Zhang, Y. Ma, F. Zhang, R. Tian, Q. Ni, S. Cheng, Z. Wang, N. Lu, B.C. Yung, Z. Wang, L. Lang, X. Fu, A. Jin, I.D. Weiss, H. Vishwasrao, G. Niu, H. Shroff, D.M. Klinman, R.A. Seder, X. Chen, Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy, Nat. Commun. 8 (2017), https://doi.org/10.1038/s41467-017-02191-y.
[32] T. Wang, D. Wang, H. Yu, B. Feng, F. Zhou, H. Zhang, L. Zhou, S. Jiao, Y. Li, A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors, Nat. Commun. 9 (2018) 1–12, https://doi.org/10.1038/s41467-018-03915-4.
[33] C.R. Perez, M. De Palma, Engineering dendritic cell vaccines to improve cancer immunotherapy, Nat. Commun. 10 (2019) 1–10, https://doi.org/10.1038/s41467-019-13368-y.
[34] C.B. Driscoll, M.R. Schuelke, T. Kottke, J.M. Thompson, P. Wongthida, J.M. Tonne, A.L. Huff, A. Miller, K.G. Shim, A. Molan, C. Wetmore, P. Selby, A. Samson, K. Harrington, H. Pandha, A. Melcher, J.S. Pulido, R. Harris, L. Evgin, R.G. Vile, APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy, Nat. Commun. 11 (2020) 1–14, https://doi.org/10.1038/s41467-020-14568-7.
[35] D.W. Zheng, F. Gao, Q. Cheng, P. Bao, X. Dong, J.X. Fan, W. Song, X. Zeng, S.X. Cheng, X.Z. Zhang, A vaccine-based nanosystem for initiating innate immunity and improving tumor immunotherapy, Nat. Commun. 11 (2020), https://doi.org/10.1038/s41467-020-15927-0.
[36] X. Li, X. Wang, A. Ito, N.M. Tsuji, A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity, Nat. Commun. 11 (2020), https://doi.org/10.1038/s41467-020-17637-z.
[37] S.W. Brady, Y. Liu, X. Ma, A.M. Gout, K. Hagiwara, X. Zhou, J. Wang, M. Macias, X. Chen, J. Easton, H.L. Mulder, M. Rusch, L. Wang, J. Nakitandwe, S. Lei, E.M. Davis, A. Naranjo, C. Cheng, J.M. Maris, J.R. Downing, N.K.V. Cheung, M.D. Hogarty, M.A. Dyer, J. Zhang, Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations, Nat. Commun. 11 (2020) 1–13, https://doi.org/10.1038/s41467-020-18987-4.
[38] H. Wang, A.J. Najibi, M.C. Sobral, B.R. Seo, J.Y. Lee, D. Wu, A.W. Li, C.S. Verbeke, D.J. Mooney, Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors, Nat. Commun. 11 (2020), https://doi.org/10.1038/s41467-020-19540-z.
[39] C. Liu, Y. Zhao, W. He, W. Wang, Y. Chen, S. Zhang, Y. Ma, J. Gohda, T. Ishida, T.S. Walter, R.J. Owens, D.I. Stuart, J. Ren, B. Gao, A RANKL mutant used as an inter-species vaccine for efficient immunotherapy of osteoporosis, Sci. Rep. 5 (2015) 1–11, https://doi.org/10.1038/srep14150.
[40] J. Vieweg, J. Dannull, Technology insight: vaccine therapy for prostate cancer, Nat. Clin. Pract. Urol. 2 (2005) 44–51, https://doi.org/10.1038/ncpuro0079.
[41] C.C. Wu, C.Y. Chiang, S.J. Liu, H.W. Chen, A novel recombinant fcγ receptor-targeted survivin combines with chemotherapy for efficient cancer treatment, Biomedicines 9 (2021) 1–14, https://doi.org/10.3390/biomedicines9070806.
[42] A. Titov, A. Valiullina, E. Zmievskaya, E. Zaikova, A. Petukhov, R. Miftakhova, E. Bulatov, A. Rizvanov, Advancing CAR T-cell therapy for solid tumors: lessons learned from lymphoma treatment, Cancers 12 (2020) 1–22, https://doi.org/10.3390/cancers12010125.
[43] R. Ladenstein, U. Pötschgerulrike, at poetschger@ccri, D. Valteau-couanet, R. Luksch, V. Castel, S. Ash, G. Laureys, P. Brock, J.M. Michon, C. Owenscormac, , owens@olchc.ie, T. Trahair, G.C.F. Chan, E. Ruud, H. Schroeder, M. Beck-popovic, G. Schreier, H. Loibner, P. Ambros, K. Holmes, M.R. Castellani, M.N. Gaze, A. Garaventa, A.D.J. Pearson, H.N. Lode, Investigation of the role of dinutuximab beta-based immunotherapy in the siopen high-risk neuroblastoma 1 trial (HR-NBL1), Cancers 12 (2020) 1–19, https://doi.org/10.3390/cancers12020309.
[44] D. Bansal, M.A. Reimers, E.M. Knoche, R.K. Pachynski, Immunotherapy and immunotherapy combinations in metastatic castration-resistant prostate cancer, Cancers 13 (2021) 1–22, https://doi.org/10.3390/cancers13020334.
[45] C.T. Stump, G. Ho, C. Mao, F.A. Veliz, V. Beiss, J. Fields, N.F. Steinmetz, S. Fiering, Remission-stage ovarian cancer cell vaccine with cowpea mosaic virus adjuvant prevents tumor growth, Cancers 13 (2021) 1–16, https://doi.org/10.3390/cancers13040627.
[46] P.G. Lokhov, E.E. Balashova, Antigenic essence: upgrade of cellular cancer vaccines, Cancers 13 (2021) 1–14, https://doi.org/10.3390/cancers13040774.
[47] L.A. Horn, K. Fousek, D.H. Hamilton, J.W. Hodge, J.A. Zebala, D.Y. Maeda, J. Schlom, C. Palena, Vaccine increases the diversity and activation of intratumoral T cells in the context of combination immunotherapy, Cancers 13 (2021) 1–17, https://doi.org/10.3390/cancers13050968.
[48] E.G. Shackleton, H.Y. Ali, M. Khan, G.A. Pockley, S.E. McArdle, Novel combinatorial approaches to tackle the immunosuppressive microenvironment of prostate cancer, Cancers 13 (2021) 1–39, https://doi.org/10.3390/cancers13051145.
[49] J. Mora, A. Castañeda, M.C. Colombo, M. Gorostegui, F. Gomez, S. Mañe, V. Santamaria, M. Garraus, N. Macias, S. Perez-jaume, O. Muñoz, J.P. Muñoz, I. Barber, M. Suñol, Clinical and pathological evidence of anti-gd2 immunotherapy induced differentiation in relapsed/refractory high-risk neuroblastoma, Cancers 13 (2021) 1–18, https://doi.org/10.3390/cancers13061264.
[50] J. Godlewski, M. Farhath, F.L. Ricklefs, C. Passaro, K. Kiel, H. Nakashima, E.A. Chiocca, A. Bronisz, Oncolytic virus therapy alters the secretome of targeted glioblastoma cells, Cancers 13 (2021) 1–20, https://doi.org/10.3390/cancers13061287.
[51] S. Cuzzubbo, A.F. Carpentier, Applications of melanin and melanin-like nanoparticles in cancer therapy: a review of recent advances, Cancers 13 (2021), https://doi.org/10.3390/cancers13061463.
[52] I.S. Pateras, A. Kotsakis, M. Avgeris, E. Baliou, P. Kouroupakis, E. Patsea, V. Georgoulias, J. Menez-Jamet, J.P. Kinet, K. Kosmatopoulos, Clinical activity of an htert-specific cancer vaccine (Vx-001) in "immune desert" NSCLC, Cancers 13 (2021) 1–13, https://doi.org/10.3390/cancers13071658.
[53] C. Giacobino, M. Canta, C. Fornaguera, S. Borrós, V. Cauda, Extracellular vesicles and their current role in cancer immunotherapy, Cancers 13 (2021) 1–24, https://doi.org/10.3390/cancers13092280.
[54] K. Matsuo, O. Yoshie, K. Kitahata, M. Kamei, Y. Hara, T. Nakayama, Recent progress in dendritic cell-based cancer immunotherapy, Cancers 13 (2021) 1–20, https://doi.org/10.3390/cancers13102495.
[55] G.J. Pegna, N. Roper, R.N. Kaplan, E. Bergsland, K. Kiseljak-vassiliades, M.A. Habra, Y. Pommier, J. Del Rivero, The immunotherapy landscape in adrenocortical cancer, Cancers 13 (2021), https://doi.org/10.3390/cancers13112660.
[56] A.E. Quamine, M.R. Olsen, M.M. Cho, C.M. Capitini, Approaches to enhance natural killer cell-based immunotherapy for pediatric solid tumors, Cancers 13 (2021) 1–29, https://doi.org/10.3390/cancers13112796.
[57] H. Hu, N.F. Steinmetz, Development of a virus-like particle-based Anti-HER2 breast cancer vaccine, Cancers 13 (2021) 1–14, https://doi.org/10.3390/cancers13122909.
[58] K. Peltonen, S. Feola, H.M. Umer, J. Chiaro, G. Mermelekas, E. Ylösmäki, S. Pesonen, R.M.M. Branca, J. Lehtiö, V. Cerullo, Therapeutic cancer vaccination with immunopeptidomics-discovered antigens confers protective antitumor efficacy, Cancers 13 (2021), https://doi.org/10.3390/cancers13143408.
[59] F.E.F. Timmer, B. Geboers, S. Nieuwenhuizen, M. Dijkstra, E.A.C. Schouten, R.S. Puijk, J.J.J. de Vries, M. Petrousjka van den Tol, A.M.E. Bruynzeel, M.M. Streppel, J.W. Wilmink, H.J. van der Vliet, M.R. Meijerink, H.J. Scheffer, T.D. de Gruijl, Pancreatic cancer and immunotherapy: a clinical overview, Cancers 13 (2021), https://doi.org/10.3390/cancers13164138.
[60] P. Cancer, Pancreatic Cancer (2021) 1–18.
[61] J. Singer, N. Le, D. Mattes, V. Klamminger, K. Hackner, N. Kolinsky, M. Scherb, P. Errhalt, G. Kreye, M. Pecherstorfer, S. Vallet, K. Podar, Evaluation of Antibody Responses to COVID-19 Vaccines Among Solid Tumor and Hematologic Patients, 2021, pp. 1–15.
[62] E. Brandetti, C. Focaccetti, A. Pezzolo, M. Ognibene, V. Folgiero, N. Cotugno, M. Benvenuto, P. Palma, V. Manzari, P. Rossi, D. Fruci, R. Bei, L. Cifaldi, Enhancement of Neuroblastoma NK-Cell-Mediated Lysis through NF-kB P65 Subunit-Induced Expression of Poor Patient Outcome, 2021.
[63] P. Zage, Novel therapies for relapsed and refractory neuroblastoma, Children 5 (2018) 148, https://doi.org/10.3390/children5110148.
[64] S. Janczar, M. Bulas, J. Walenciak, D. Baranska, Pulmonary Exacerbation of Undiagnosed Toxocariasis, 2020.
[65] M. Metzen, M. Bruns, W. Deppert, U. Schumacher, Infiltration of immune competent cells into primary tumors and their surrounding connective tissues in xenograft and syngeneic mouse models, Int. J. Mol. Sci. 22 (2021), https://doi.org/10.3390/ijms22084213.
[66] C.G. Kim, Y.B. Sang, J.H. Lee, H.J. Chon, Combining cancer vaccines with immunotherapy: establishing a new immunological approach, Int. J. Mol. Sci. 22 (2021), https://doi.org/10.3390/ijms22158035.
[67] M.Y. Zanna, A.R. Yasmin, A.R. Omar, S.S. Arshad, A.R. Mariatulqabtiah, S.H. Nur-Fazila, M.I.N. Mahiza, Review of dendritic cells, their role in clinical immunology,

and distribution in various animal species, Int. J. Mol. Sci. 22 (2021), https://doi.org/10.3390/ijms22158044.
[68] Q. Wang, Building Personalized Cancer Therapeutics through Multi-Omics Assays and Bacteriophage-Eukaryotic Cell Interactions, 2021.
[69] A. Gautam, V. Beiss, C. Wang, L. Wang, N.F. Steinmetz, Plant Viral Nanoparticle Conjugated with Anti-PD-1 Peptide for Ovarian Cancer Immunotherapy, 2021.
[70] C. Hochheuser, N.Y. Kunze, G.A.M. Tytgat, C. Voermans, I. Timmerman, The potential of mesenchymal stromal cells in neuroblastoma therapy for delivery of anti-cancer agents and hematopoietic recovery, J. Personalized Med. 11 (2021) 1–24, https://doi.org/10.3390/jpm11030161.
[71] I.J. Guldvik, L. Ekseth, A. Kishan, A. Stensvold, E.M. Inderberg, W. Lilleby, Circulating tumor cell persistence associates with long-term clinical outcome to a therapeutic cancer vaccine in prostate cancer, J. Personalized Med. 11 (2021), https://doi.org/10.3390/jpm11070605.
[72] J. Heuts, W. Jiskoot, F. Ossendorp, K. Van Der Maaden, Cationic Nanoparticle-Based Cancer Vaccines, 2021, pp. 1–19.
[73] L.S. Mbatha, F. Maiyo, A. Daniels, M. Singh, Dendrimer-coated gold nanoparticles for efficient folate-targeted mRNA delivery in vitro, Pharmaceutics 13 (2021), https://doi.org/10.3390/pharmaceutics13060900.
[74] M.K.N. Twilhaar, L. Czentner, C.F. van Nostrum, G. Storm, J.M.M. Den Haan, Mimicking pathogens to augment the potency of liposomal cancer vaccines, Pharmaceutics 13 (2021) 1–20, https://doi.org/10.3390/pharmaceutics13070954.
[75] R. Neupane, S.H.S. Boddu, M.S. Abou-Dahech, R.D. Bachu, D. Terrero, R.J. Babu, A.K. Tiwari, Transdermal Delivery of Chemotherapeutics: Strategies, Requirements, and Opportunities, 2021, https://doi.org/10.3390/pharmaceutics13070960.
[76] M. Tusup, S. Läuchli, N.T. Jarzebska, L.E. French, Y.T. Chang, M. Vonow-Eisenring, A. Su, T.M. Kündig, E. Guenova, S. Pascolo, mRNA-based anti-TCR CDR3 tumour vaccine for T-cell lymphoma, Pharmaceutics 13 (2021), https://doi.org/10.3390/pharmaceutics13071040.
[77] Y. Pan, X. Song, Y. Wang, J. Wei, Firing up the Tumor Microenvironment with Nanoparticle-Based Therapies, 2021, pp. 1–16.
[78] S. Aktas, A.P.E. Ozdemir, E.O. Serinan, Z. Altun, N. Olgun, Don't eat me" signals of neuroblastoma by CD47 for immune escape: a novel prognostic biomarker, Proceedings 2 (2018) 1538, https://doi.org/10.3390/proceedings2251538.
[79] P. Sawaisorn, K. Atjanasuppat, U. Anurathapan, S. Chutipongtanate, S. Hongeng, Strategies to improve chimeric antigen receptor therapies for neuroblastoma, Vaccines 8 (2020) 1–28, https://doi.org/10.3390/vaccines8040753.
[80] Y. Zhao, A.V. Baldin, O. Isayev, J. Werner, A.A. Zamyatnin, A.V. Bazhin, Cancer vaccines: antigen selection strategy, Vaccines 9 (2021) 1–30, https://doi.org/10.3390/vaccines9020085.
[81] N. Pardi, Mrna innovates the vaccine field, Vaccines 9 (2021), https://doi.org/10.3390/vaccines9050486.
[82] B. Wolfson, S.E. Franks, J.W. Hodge, Stay on target: reengaging cancer vaccines in combination immunotherapy, Vaccines 9 (2021), https://doi.org/10.3390/vaccines9050509.
[83] B.Q. Tay, Q. Wright, R. Ladwa, C. Perry, G. Leggatt, F. Simpson, J.W. Wells, B.J. Panizza, I.H. Frazer, J.L.G. Cruz, Evolution of cancer vaccines—challenges, achievements, and future directions, Vaccines 9 (2021), https://doi.org/10.3390/vaccines9050535.
[84] B.A. Maiorano, G. Schinzari, D. Ciardiello, M.G. Rodriquenz, A. Cisternino, G. Tortora, E. Maiello, Cancer vaccines for genitourinary tumors: recent progresses and future possibilities, Vaccines 9 (2021), https://doi.org/10.3390/vaccines9060623.
[85] H. Donninger, C. Li, J.W. Eaton, K. Yaddanapudi, Cancer vaccines: promising therapeutics or an unattainable dream, Vaccines 9 (2021) 1–30, https://doi.org/10.3390/vaccines9060668.
[86] B.N. Aldosari, I.M. Alfagih, A.S. Almurshedi, Lipid nanoparticles as delivery systems for RNA-based vaccines, Pharmaceutics 13 (2021) 1–29, https://doi.org/10.3390/pharmaceutics13020206.
[87] W.M. Kholosy, M. Derieppe, F. Van Den Ham, K. Ober, Y. Su, L. Custers, L. Schild, L.M.J. Van Zogchel, L.M. Wellens, H.R. Ariese, C.L. Szanto, J. Wienke, M.P. Dierselhuis, D. Van Vuurden, E.M. Dolman, J.J. Molenaar, Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies, 2021.
[88] S.E. Barker, S.M. Grosse, E.K. Siapati, A. Kritz, C. Kinnon, A.J. Thrasher, S.L. Hart, Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12, Br. J. Cancer 97 (2007) 210–217, https://doi.org/10.1038/sj.bjc.6603857.
[89] N. Chaudhary, D. Weissman, K.A. Whitehead, mRNA vaccines for infectious diseases: principles, delivery and clinical translation, Nat. Rev. Drug Discov. (2021), 0123456789, https://doi.org/10.1038/s41573-021-00283-5.
[90] E. Blass, P.A. Ott, Advances in the development of personalized neoantigen-based therapeutic cancer vaccines, Nat. Rev. Clin. Oncol. 18 (2021) 215–229, https://doi.org/10.1038/s41571-020-00460-2.
[91] V. Rigo, L. Emionite, A. Daga, S. Astigiano, M.V. Corrias, C. Quintarelli, F. Locatelli, S. Ferrini, M. Croce, Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma, Sci. Rep. 7 (2017) 1–13, https://doi.org/10.1038/s41598-017-14417-6.
[92] I. Knezevic, M.A. Liu, K. Peden, T. Zhou, H. Kang, Dev. mRNA Vacc. : Sci. Regul. Iss. (2021) 1–10.
[93] A. Flemming, mRNA vaccine shows promise in autoimmunity, Nat. Rev. Immunol. 153 (2021) 41577, https://doi.org/10.1038/s41577-021-00504-3.
[94] N. Pardi, M.J. Hogan, D. Weissman, ScienceDirect Recent advances in mRNA vaccine technology, Curr. Opin. Immunol. 65 (n.d.) 14–20. https://doi.org/10.1016/j.coi.2020.01.008.
[95] S. Linares-ferna, Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response, 2019, pp. 1–13, https://doi.org/10.1016/j.molmed.2019.10.002.
[96] N. Pardi, M.J. Hogan, F.W. Porter, D. Weissman, N. Carolina, mRNA vaccines — a new era in vaccinol. 17 (2018) 261–279, https://doi.org/10.1038/nrd.2017.243.mRNA.
[97] G. Cafri, J.J. Gartner, T. Zaks, K. Hopson, N. Levin, B.C. Paria, M.R. Parkhurst, R. Yossef, F.J. Lowery, M.S. Jafferji, T.D. Prickett, S.L. Goff, C.T. Mcgowan, S. Seitter, M.L. Shindorf, A. Parikh, P.D. Chatani, P.F. Robbins, S.A. Rosenberg, mRNA Vaccine – Induced Neoantigen-specific T Cell Immunity in Patients with Gastrointestinal Cancer, 2020, p. 130.
[98] S. Xu, K. Yang, R. Li, L. Zhang, mRNA Vaccine Era — Mechanisms, Drug Platform and Clinical Prospection, 2020.
[99] U. Sahin, K. Karikó, Ö. Türeci, MRNA-based therapeutics-developing a new class of drugs, Nat. Rev. Drug Discov. 13 (2014) 759–780, https://doi.org/10.1038/nrd4278.
[100] E. Faghfuri, F. Pourfarzi, A.H. Faghfouri, M. Abdoli Shadbad, K. Hajiasgharzadeh, B. Baradaran, Recent developments of RNA-based vaccines in cancer immunotherapy, Expert Opin, Biol. Ther. 21 (2021) 201–218, https://doi.org/10.1080/14712598.2020.1815704.
[101] I.V. Kholodenko, D.V. Kalinovsky, I.I. Doronin, S.M. Deyev, R.V. Kholodenko, Neuroblastoma origin and therapeutic targets for immunotherapy, J. Immunol. Res. 2018 (2018), https://doi.org/10.1155/2018/7394268.
[103] P.S. Hegde, D.S. Chen, Perspective top 10 challenges in cancer immunotherapy, Immunity 52 (2020) 17–35, https://doi.org/10.1016/j.immuni.2019.12.011.
[104] K. Das, E. Belnoue, M. Rossi, T. Hofer, S. Danklmaier, T. Nolden, L.-M. Schreiber, K. Angerer, J. Kimpel, S. Hoegler, B. Spiesschaert, L. Kenner, D. von Laer, K. Elbers, M. Derouazi, G. Wollmann, A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity, Nat. Commun. 12 (2021) 1–14, https://doi.org/10.1038/s41467-021-25506-6.
[105] W. Phumrattanaprapin, M. Pearson, D. Pickering, B. Tedla, M. Smout, S. Chaiyadet, P.J. Brindley, A. Loukas, T. Laha, Monoclonal antibodies targeting an opisthorchis viverrini extracellular vesicle tetraspanin protect hamsters against challenge infection, Vaccines 9 (2021), https://doi.org/10.3390/vaccines9070740.
[106] J. Koerner, D. Horvath, V.L. Herrmann, A. MacKerracher, B. Gander, H. Yagita, J. Rohayem, M. Groettrup, PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy, Nat. Commun. 12 (2021) 1–16, https://doi.org/10.1038/s41467-021-23244-3.
[107] M. Yazdani, Z. Gholizadeh, A.R. Nikpoor, N. Mohamadian Roshan, M.R. Jaafari, A. Badiee, Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy, Sci. Rep. 11 (2021) 1–12, https://doi.org/10.1038/s41598-021-94250-0.
[108] D. Sahin, N. Arenas-Ramirez, M. Rath, U. Karakus, M. Hümbelin, M. van Gogh, L. Borsig, O. Boyman, An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer, Nat. Commun. 11 (2020) 1–12, https://doi.org/10.1038/s41467-020-20220-1.
[109] G. Agliardi, A.R. Liuzzi, A. Hotblack, D. De Feo, N. Núñez, C.L. Stowe, E. Friebel, F. Nannini, L. Rindlisbacher, T.A. Roberts, R. Ramasawmy, I.P. Williams, B.M. Siow, M.F. Lythgoe, T.L. Kalber, S.A. Quezada, M.A. Pule, S. Tugues, K. Straathof, B. Becher, Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma, Nat. Commun. 12 (2021) 1–11, https://doi.org/10.1038/s41467-020-20599-x.
[110] L. Su, Y. Zhang, X. Zhang, T. Liu, S. Liu, Y. Li, M. Jiang, T. Tang, H. Shen, C. Wang, Combination immunotherapy with two attenuated Listeria strains carrying shuffled HPV-16 E6E7 protein causes tumor regression in a mouse tumor model, Sci. Rep. 11 (2021) 1–12, https://doi.org/10.1038/s41598-021-92875-9.
[111] V. Morante, M. Borghi, I. Farina, Z. Michelini, F. Grasso, A. Gallinaro, S. Cecchetti, A. Di Virgilio, A. Canitano, M.F. Pirillo, R. Bona, A. Cara, D. Negri, Integrase-defective lentiviral vector is an efficient vaccine platform for cancer immunotherapy, Viruses 13 (2021) 1–18, https://doi.org/10.3390/v13020355.
[112] A. Kudva, S. Modak, Immunotherapy for neuroblastoma, neuroblastoma mol, Mech. Ther. Interv (2019) 147–173, https://doi.org/10.1016/B978-0-12-812005-7.00009-6.
[113] L. Spel, A. Schiepers, M. Boes, NFκB and MHC-1 interplay in neuroblastoma and immunotherapy, Trends in Cancer 4 (2018) 715–717, https://doi.org/10.1016/j.trecan.2018.09.006.
[114] O. Melaiu, M. Chierici, V. Lucarini, G. Jurman, L.A. Conti, R. De Vito, R. Boldrini, L. Cifaldi, A. Castellano, C. Furlanello, V. Barnaba, F. Locatelli, D. Fruci, Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma, Nat. Commun. 11 (2020) 1–15, https://doi.org/10.1038/s41467-020-19781-y.
[115] F. Morandi, F. Frassoni, M. Ponzoni, C. Brignole, Novel immunotherapeutic approaches for neuroblastoma and malignant melanoma, J. Immunol. Res. 2018 (2018), https://doi.org/10.1155/2018/8097398.
[116] G. Pelizzo, V. Veschi, M. Mantelli, S. Croce, V. Di Benedetto, P. D'Angelo, A. Maltese, L. Catenacci, T. Apuzzo, E. Scavo, A. Moretta, M. Todaro, G. Stassi, M.A. Avanzini, V. Calcaterra, Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells, BMC Cancer 18 (2018) 1–12, https://doi.org/10.1186/s12885-018-5082-2.
[117] D. De Pooter, E. Van Gulck, A. Chen, C.F. Evans, J. Neefs, H. Horton, D. Boden, A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-human Primates, 2021.

[118] S.L. George, F. Lorenzi, D. King, S. Hartlieb, J. Campbell, H. Pemberton, U.H. Toprak, K. Barker, J. Tall, B.M. da Costa, M.L. van den Boogaard, M.E.M. Dolman, J.J. Molenaar, H.E. Bryant, F. Westermann, C.J. Lord, L. Chesler, Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma, EBioMedicine 59 (2020) 102971, https://doi.org/10.1016/j.ebiom.2020.102971.

[119] R.M. Trigg, J.A. Shaw, S.D. Turner, Opportunities and challenges of circulating biomarkers in neuroblastoma, Open Biol. 9 (2019), https://doi.org/10.1098/rsob.190056.

[120] W.-J. Yang, Y.-Y. Zhou, F. Zhao, Z.-M. Mei, S. Li, Y. Xiang, Orbital neuroblastoma metastasis, Medicine (Baltim.) 98 (2019), e17038, https://doi.org/10.1097/md.0000000000017038.

[121] B. Hassannia, B. Wiernicki, I. Ingold, F. Qu, S. Van Herck, Y.Y. Tyurina, H. Bayir, B.A. Abhari, J.P.F. Angeli, S.M. Choi, E. Meul, K. Heyninck, K. Declerck, C.S. Chirumamilla, M. Lahtela-Kakkonen, G. Van Camp, D.V. Krysko, P.G. Ekert, S. Fulda, B.G. De Geest, M. Conrad, V.E. Kagan, W. Vanden Berghe, P. Vandenabeele, T. Vanden Berghe, Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma, J. Clin. Invest. 128 (2018) 3341–3355, https://doi.org/10.1172/JCI99032.

[122] K.R. Bosse, P. Raman, Z. Zhu, M. Lane, D. Martinez, S. Heitzeneder, K.S. Rathi, N.M. Kendsersky, M. Randall, L. Donovan, S. Morrissy, R.T. Sussman, D.V. Zhelev, Y. Feng, Y. Wang, J. Hwang, G. Lopez, J.L. Harenza, J.S. Wei, B. Pawel, T. Bhatti, M. Santi, A. Ganguly, J. Khan, M.A. Marra, M.D. Taylor, D.S. Dimitrov, C.L. Mackall, J.M. Maris, Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma, Cancer Cell 32 (2017) 295–309, https://doi.org/10.1016/j.ccell.2017.08.003, e12.

[123] J.C. Nolan, T. Frawley, J. Tighe, H. Soh, C. Curtin, O. Piskareva, Preclinical models for neuroblastoma: advances and challenges, Cancer Lett. 474 (2020) 53–62, https://doi.org/10.1016/j.canlet.2020.01.015.

[124] L. Jubierre, C. Jiménez, E. Rovira, A. Soriano, C. Sábado, L. Gros, A. Llort, R. Hladun, J. Roma, J.S. de Toledo, S. Gallego, M.F. Segura, Targeting of epigenetic regulators in neuroblastoma, Exp. Mol. Med. 50 (2018), https://doi.org/10.1038/s12276-018-0077-2.

[125] S.L. George, V. Parmar, F. Lorenzi, L.V. Marshall, Y. Jamin, E. Poon, P. Angelini, L. Chesler, Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma, J. Exp. Clin. Cancer Res. 39 (2020) 1–10, https://doi.org/10.1186/s13046-020-01582-2.

[126] Y. Zeng, Y. Xiang, R. Sheng, H. Tomás, J. Rodrigues, Z. Gu, H. Zhang, Q. Gong, K. Luo, Polysaccharide-based nanomedicines for cancer immunotherapy: a review, Bioact. Mater. 6 (2021) 3358–3382, https://doi.org/10.1016/j.bioactmat.2021.03.008.

[127] H. Mashima, R. Zhang, T. Kobayashi, H. Tsukamoto, T. Liu, T. Iwama, Y. Hagiya, M. Yamamoto, S. Fukushima, S. Okada, A. Idiris, S. Kaneko, T. Nakatsura, H. Ohdan, Y. Uemura, Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy, Mol. Ther. - Methods Clin. Dev. 21 (2021) 171–179, https://doi.org/10.1016/j.omtm.2021.03.002.

[128] N.R. Pinto, M.A. Applebaum, S.L. Volchenboum, K.K. Matthay, W.B. London, P.F. Ambros, A. Nakagawara, F. Berthold, G. Schleiermacher, J.R. Park, D. Valteau-Couanet, A.D.J. Pearson, S.L. Cohn, Advances in risk classification and treatment strategies for neuroblastoma, J. Clin. Oncol. 33 (2015) 3008–3017, https://doi.org/10.1200/JCO.2014.59.4648.

[129] D. Coughlan, M. Gianferante, C.F. Lynch, J.L. Stevens, C. Harlan, from a Population-Based Study in the United States 34 (2019) 320–330, https://doi.org/10.1080/08880018.2017.1373315.Treatment.

[130] H. Li, H. Wu, Q. Wang, S. Ning, S. Xu, D. Pang, Dual effects of N6-methyladenosine on cancer progression and immunotherapy, Mol. Ther. Nucleic Acids 24 (2021) 25–39, https://doi.org/10.1016/j.omtn.2021.02.001.

[131] L.P. Rhea, S. Mendez-Marti, D. Kim, J.B. Aragon-Ching, Role of immunotherapy in bladder cancer, Cancer Treat. Res. Commun. 26 (2021) 100296, https://doi.org/10.1016/j.ctarc.2020.100296.

[132] L. Yuan, J. Tatineni, K.M. Mahoney, G.J. Freeman, VISTA: a mediator of quiescence and a promising target in cancer immunotherapy, Trends Immunol. 42 (2021) 209–227, https://doi.org/10.1016/j.it.2020.12.008.

[133] S. Chaudhuri, S. Thomas, P. Munster, Immunotherapy in breast cancer: a clinician's perspective, J. Natl. Cancer Cent. 1 (2021) 47–57, https://doi.org/10.1016/j.jncc.2021.01.001.

[134] Z. Lu, Z. Peng, C. Liu, Z. Wang, Y. Wang, X. Jiao, J. Li, L. Shen, Current status and future perspective of immunotherapy in gastrointestinal cancers, innovation(China), 1, 100041, https://doi.org/10.1016/j.xinn.2020.100041, 2020.

[135] M. Yang, J. Li, P. Gu, X. Fan, The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment, Bioact. Mater. 6 (2021), https://doi.org/10.1016/j.bioactmat.2020.12.010, 1973–1987.

[136] S.H. Kiaie, M.J. Sanaei, M. Heshmati, Z. Asadzadeh, I. Azimi, S. Hadidi, R. Jafari, B. Baradaran, Immune checkpoints in targeted-immunotherapy of pancreatic cancer: new hope for clinical development, Acta Pharm. Sin. B. 11 (2021) 1083–1097, https://doi.org/10.1016/j.apsb.2020.12.011.

[137] S.B. Whittle, V. Smith, E. Doherty, S. Zhao, S. McCarty, P.E. Zage, Overview and recent advances in the treatment of neuroblastoma, Expert Rev. Anticancer Ther. 17 (2017) 369–386, https://doi.org/10.1080/14737140.2017.1285230.

[138] Y. Xu, Z. Zhang, G. Xu, TRIM proteins in neuroblastoma, Biosci. Rep. 39 (2019) 1–9, https://doi.org/10.1042/BSR20192050.

[143] L.M. Wellens, M.M. Deken, C.F.M. Sier, H.R. Johnson, F. de la Jara Ortiz, S.S. Bhairosingh, R.D. Houvast, W.M. Kholosy, V.M. Baart, A.M.M.J. Pieters, R.R. de Krijger, J.J. Molenaar, E.J. Wehrens, J.F. Dekkers, M.H.W.A. Wijnen, A.L. Vahrmeijer, A.C. Rios, Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma, Sci. Rep. 10 (2020) 1–12, https://doi.org/10.1038/s41598-020-74464-4.

[144] dr madhu Nagla, 乳鼠心肌提取 HHS Public Access, Physiol. Behav. 176 (2016) 100–106, https://doi.org/10.1007/s00441-017-2761-2.Spontaneous.

[145] N.J.N.N.P.S. Daniel E Shumer, 乳鼠心肌提取 HHS Public Access, Physiol. Behav. 176 (2017) 139–148, https://doi.org/10.1080/14737140.2017.1364995.Anti-GD2.

[146] S. Påhlman, S. Mohlin, Hypoxia and hypoxia-inducible factors in neuroblastoma, Cell Tissue Res. 372 (2018) 269–275, https://doi.org/10.1007/s00441-017-2701-1.

[147] C.U. Louis, J.M. Shohet, Neuroblastoma: molecular pathogenesis and therapy, Annu. Rev. Med. 66 (2015) 49–63, https://doi.org/10.1146/annurev-med-011514-023121.

[148] V.P. Tolbert, G.E. Coggins, J.M. Maris, J.M. Maris, Genetic susceptibility to neuroblastoma, Curr. Opin. Genet. Dev. 42 (2017) 81–90, https://doi.org/10.1016/j.gde.2017.03.008.

[149] I. Situ, C. Vaccination, I. Using, in Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV, 2021, pp. 1–27.

[150] L. Bai, W. Li, W. Zheng, D. Xu, N. Chen, J. Cui, Promising targets based on pattern recognition receptors for cancer immunotherapy, Pharmacol. Res. 159 (2020) 105017, https://doi.org/10.1016/j.phrs.2020.105017.

[151] S. Azghadi, M.E. Daly, Radiation and immunotherapy combinations in non-small cell lung cancer, Cancer Treat. Res. Commun. 26 (2021) 100298, https://doi.org/10.1016/j.ctarc.2020.100298.

[152] B. Amaoui, I. Lalya, F. Safini, S. Semghouli, Combination of immunotherapy-radiotherapy in non small cell lung cancer: reality and perspective, Radiat. Med. Prot (2021), https://doi.org/10.1016/j.radmp.2021.09.002.

[153] D. Waterhouse, J. Lam, K.A. Betts, L. Yin, S. Gao, Y. Yuan, J. Hartman, S. Rao, S. Lubinga, D. Stenehjem, Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset, Data Brief 37 (2021) 107195, https://doi.org/10.1016/j.dib.2021.107195.

[154] M. Jiang, K. Jia, L. Wang, W. Li, B. Chen, Y. Liu, H. Wang, S. Zhao, Y. He, C. Zhou, Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy, Acta Pharm. Sin. B (2021), https://doi.org/10.1016/j.apsb.2021.01.003.

[155] D. Lobenwein, F. Kocher, S. Dobner, C. Gollmann-Tepeköylü, J. Holfeld, Cardiotoxic mechanisms of cancer immunotherapy – a systematic review, Int. J. Cardiol. 323 (2021) 179–187, https://doi.org/10.1016/j.ijcard.2020.08.033.

[156] D. Streel, S. Lucas, Targeting Immunosuppression by TGF- β 1 for Cancer Immunotherapy, 2021, p. 192, https://doi.org/10.1016/j.bcp.2021.114697.

[157] L. Fang, Z. Zhao, J. Wang, P. Xiao, X. Sun, Y. Ding, P. Zhang, D. Wang, Y. Li, Light-controllable charge-reversal nanoparticles with polyinosinic-polycytidylic acid for enhancing immunotherapy of triple negative breast cancer, Acta Pharm. Sin. B (2021), https://doi.org/10.1016/j.apsb.2021.06.006.

[158] X. Bai, J. Ni, J. Beretov, P. Graham, Y. Li, Immunotherapy for triple-negative breast cancer: a molecular insight into the microenvironment, treatment, and resistance, J. Natl. Cancer Cent. (2021), https://doi.org/10.1016/j.jncc.2021.06.001.

[159] X. Meng, X. Sun, Z. Liu, Y. He, A novel era of cancer/testis antigen in cancer immunotherapy, Int. Immunopharm. 98 (2021) 107889, https://doi.org/10.1016/j.intimp.2021.107889.

[160] I. Terrén, A. Orrantia, J. Vitallé, G. Astarloa-Pando, O. Zenarruzabeitia, F. Borrego, Modulating NK cell metabolism for cancer immunotherapy, Semin. Hematol. 57 (2020) 213–224, https://doi.org/10.1053/j.seminhematol.2020.10.003.

[161] M. Jiang, L. Zhao, X. Cui, X. Wu, Y. Zhang, X. Guan, J. Ma, W. Zhang, Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy, J. Adv. Res. (2021), https://doi.org/10.1016/j.jare.2021.08.011.

[162] M.A. Franzoi, E. Romano, M. Piccart, Immunotherapy for early breast cancer: too soon, too superficial, or just right? Ann. Oncol. 32 (2021) 323–336, https://doi.org/10.1016/j.annonc.2020.11.022.

[163] Y. Pan, K.E. Kadash-Edmondson, R. Wang, J. Phillips, S. Liu, A. Ribas, R. Aplenc, O.N. Witte, Y. Xing, RNA dysregulation: an expanding source of cancer immunotherapy targets, Trends Pharmacol. Sci. 42 (2021) 268–282, https://doi.org/10.1016/j.tips.2021.01.006.

[164] M. Ouwens, A. Darilay, Y. Zhang, P. Mukhopadhyay, H. Mann, J. Ryan, P.A. Dennis, Assessing the influence of subsequent immunotherapy on overall survival in patients with unresectable stage III non–small cell lung cancer from the PACIFIC study, Curr. Ther. Res. 95 (2021) 100640, https://doi.org/10.1016/j.curtheres.2021.100640.

[165] D. Özcan, J. Lade-Keller, T. Tramm, Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy? Pathol. Res. Pract. 226 (2021) 153606, https://doi.org/10.1016/j.prp.2021.153606.

[166] C. Sardeli, P. Zarogoulidis, K. Romanidis, P. Oikonomou, K. Sapalidis, H. Huang, C. Bai, W. Hohenforst-Schmidt, K. Tsakiridis, B. Zaric, B. Perin, A. Ioannidis, S. Baka, K. Drevelegas, M. Kosmidou, C. Kosmidis, Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer, Respir. Med. Case Reports 31 (2020) 101258, https://doi.org/10.1016/j.rmcr.2020.101258.

[167] L. Guerra, L. Bonetti, D. Brenner, Metabolic modulation of immunity: a new concept in cancer immunotherapy, Cell Rep. 32 (2020) 107848, https://doi.org/10.1016/j.celrep.2020.107848.

[168] D. Cibula, L. Rob, P. Mallmann, P. Knapp, J. Klat, J. Chovanec, L. Minar, B. Melichar, A. Hein, D. Kieszko, M. Pluta, J. Spacek, P. Bartos, P. Wimberger, R. Madry, J. Markowska, J. Streb, P. Valha, H.I. Bin Hassan, L. Pecen, L. Galluzzi, J. Fucikova, T. Hrnciarova, M. Hraska, J. Bartunkova, R. Spisek, Dendritic cell-

based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): a randomized, open-label, phase 2 trial, Gynecol. Oncol. 162 (2021) 652–660, https://doi.org/10.1016/j.ygyno.2021.07.003.
[169] E. García-Martínez, J.A. Pérez-Fidalgo, Immunotherapies in ovarian cancer, Eur. J. Cancer, Suppl. 15 (2020) 87–95, https://doi.org/10.1016/j.ejcsup.2020.02.002.
[170] 1-s2.0-S221112472100019X-main.pdf, (n.d.).
[171] 1-s2.0-S2452199X21001031-main.pdf, (n.d.).
[172] 1-s2.0-S1476558621000026-main.pdf, (n.d.).
[173] 1-s2.0-S2372770521000917-main.pdf, (n.d.).
[174] T.J. Li, W.Q. Wang, X.J. Yu, L. Liu, Killing the "BAD": challenges for immunotherapy in pancreatic cancer, Biochim. Biophys. Acta Rev. Canc 1874 (2020) 188384, https://doi.org/10.1016/j.bbcan.2020.188384.
[175] R. Barrett, E. Puré, Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy, Curr. Opin. Immunol. 64 (2020) 80–87, https://doi.org/10.1016/j.coi.2020.03.004.
[176] N. Sumransub, K. Vantanasiri, A. Prakash, E. Lou, Advances and new frontiers for immunotherapy in colorectal cancer: setting the stage for neoadjuvant success? Mol. Ther. - Oncolytics. 22 (2021) 1–12, https://doi.org/10.1016/j.omto.2021.05.001.
[177] S. Zhou, W. Chen, J. Cole, G. Zhu, Delivery of nucleic acid therapeutics for cancer immunotherapy, Med. Drug Discov. 6 (2020) 100023, https://doi.org/10.1016/j.medidd.2020.100023.
[178] A.T. Nguyen, S.L. Shiao, H.L. McArthur, Advances in combining radiation and immunotherapy in breast cancer, Clin. Breast Cancer 21 (2021) 143–152, https://doi.org/10.1016/j.clbc.2021.03.007.
[179] Y. Zhu, X. Yu, S.D. Thamphiwatana, Y. Zheng, Z. Pang, Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy, Acta Pharm. Sin. B. 10 (2020) 2054–2074, https://doi.org/10.1016/j.apsb.2020.08.010.
[180] S. Tan, D. Li, X. Zhu, Cancer immunotherapy: pros, cons and beyond, biomed, Pharma 124 (2020), https://doi.org/10.1016/j.biopha.2020.109821.
[181] E.D. Carosella, S. Gregori, D. Tronik-Le Roux, HLA-G/LILRBs: a cancer immunotherapy challenge, Trends in Cancer 7 (2021) 389–392, https://doi.org/10.1016/j.trecan.2021.01.004.
[182] J.M. Lee, A.W. Kim, T. Marjanski, P.-E. Falcoz, M. Tsuboi, Y.-L. Wu, S.W. Sun, B.J. Gitlitz, Important surgical and clinical endpoints in neoadjuvant immunotherapy trials in resectable non-small cell lung cancer, JTO Clin. Res. Reports (2021) 100221, https://doi.org/10.1016/j.jtocrr.2021.100221.
[183] M.D. Vesely, L. Chen, Normalization cancer immunotherapy for melanoma, J. Invest. Dermatol. 140 (2020) 1134–1142, https://doi.org/10.1016/j.jid.2020.02.005.
[184] A. Naja, M. Merhi, V. Inchakalody, Q. Fernandes, S. Mestiri, K.S. Prabhu, S. Uddin, S. Dermime, The role of PAK4 in the immune system and its potential implication in cancer immunotherapy, Cell, Immunol. 367 (2021) 104408, https://doi.org/10.1016/j.cellimm.2021.104408.
[185] D. Lee, J. Park, H. Choi, G. Gim, S. Cho, L. Kim, Y. Oh, C.Y. Kang, Y. Kim, D. Tan, P.A.H. de Viveiros, Y.K. Chae, Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy, Heliyon 7 (2021), e07916, https://doi.org/10.1016/j.heliyon.2021.e07916.
[186] N.B. Day, W.C. Wixson, C.W. Shields, Magnetic systems for cancer immunotherapy, Acta Pharm. Sin. B. 11 (2021) 2172–2196, https://doi.org/10.1016/j.apsb.2021.03.023.
[187] M. Kossai, N. Radosevic-robin, F. Penault-llorca, Re fi ning patient selection for breast cancer immunotherapy : beyond PD-L1, ESMO Open 6 (2021) 100257, https://doi.org/10.1016/j.esmoop.2021.100257.
[188] K. Bhise, S. Sau, R. Alzhrani, M.A. Rauf, K. Tatiparti, A.K. Iyer, Imaging the cellular components of the immune system for advancing diagnosis and immunotherapy of cancers, Mater, Today Adv 10 (2021) 100138, https://doi.org/10.1016/j.mtadv.2021.100138.
[204] A. Cook, E. Bernstein, A strike against indolent neuroblastoma, EBioMedicine 60 (2020) 60–61, https://doi.org/10.1016/j.ebiom.2020.103000.
[205] Z. Hu, P.A. Ott, C.J. Wu, Towards personalized, tumour-specific, therapeutic vaccines for cancer, Nat. Rev. Immunol. 18 (2018) 168–182, https://doi.org/10.1038/nri.2017.131.
[206] K.J. Koh, Y. Liu, S.H. Lim, X.J. Loh, L. Kang, C.Y. Lim, K.K.L. Phua, Formulation, characterization and evaluation of mRNA-loaded dissolvable polymeric microneedles (RNApatch), Sci. Rep. 8 (2018) 1–11, https://doi.org/10.1038/s41598-018-30290-3.
[207] M.D. Shin, S. Shukla, Y.H. Chung, V. Beiss, S.K. Chan, O.A. Ortega-Rivera, D.M. Wirth, A. Chen, M. Sack, J.K. Pokorski, N.F. Steinmetz, COVID-19 vaccine development and a potential nanomaterial path forward, Nat. Nanotechnol. 15 (2020) 646–655, https://doi.org/10.1038/s41565-020-0737-y.
[208] V. Alimardani, S.S. Abolmaali, G. Yousefi, Z. Rahiminezhad, M. Abedi, A. Tamaddon, S. Ahadian, Microneedle arrays combined with nanomedicine approaches for transdermal delivery of therapeutics, J. Clin. Med. 10 (2021) 181, https://doi.org/10.3390/jcm10020181.
[209] T. Burki, Global COVID-19 vaccine inequity, Lancet Infect. Dis. 21 (2021) 922–923, https://doi.org/10.1016/s1473-3099(21)00344-3.
[210] H. Brüssow, Efforts towards a COVID-19 vaccine, Environ. Microbiol. 22 (2020) 4071–4084, https://doi.org/10.1111/1462-2920.15225.
[211] E. Zavala, K.C.A. Wedgwood, M. Voliotis, J. Tabak, F. Spiga, S.L. Lightman, K. Tsaneva-Atanasova, Mathematical modelling of endocrine systems, Trends Endocrinol. Metabol. 30 (2019) 244–257, https://doi.org/10.1016/j.tem.2019.01.008.
[212] M. Jeyanathan, S. Afkhami, F. Smaill, M.S. Miller, B.D. Lichty, Z. Xing, Immunological considerations for COVID-19 vaccine strategies, Nat. Rev. Immunol. 20 (2020) 615–632, https://doi.org/10.1038/s41577-020-00434-6.
[213] J. Wang, Y. Peng, H. Xu, Z. Cui, R.O. Williams, The COVID-19 vaccine race: challenges and opportunities in vaccine formulation, AAPS PharmSciTech 21 (2020) 1–12, https://doi.org/10.1208/s12249-020-01744-7.
[214] J. Stumpf, T. Siepmann, T. Lindner, C. Karger, J. Schwöbel, L. Anders, R. Faulhaber-walter, J. Schewe, H. Martin, H. Schirutschke, K. Barnett, J. Hüther, P. Müller, T. Langer, T. Pluntke, K. Anding-rost, F. Meistring, T. Stehr, A. Pietzonka, K. Escher, S. Cerny, H. Rothe, F. Pistrosch, H. Seidel, A. Paliege, J. Beige, I. Bast, A. Steglich, F. Gembardt, F. Kessel, H. Kröger, P. Arndt, J. Sradnick, K. Frank, A. Klimova, R. Mauer, X. Grählert, M. Anft, A. Blazquez-navarro, T.H. Westhoff, U. Stervbo, T. Tonn, N. Babel, C. Hugo, The Lancet Regional Health - europe Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients : a prospective , multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine, Lancet Reg. Heal. - Eur. (2021) 100178, https://doi.org/10.1016/j.lanepe.2021.100178, 000.
[215] T. Yadav, N. Srivastava, G. Mishra, K. Dhama, S. Kumar, B. Puri, S.K. Saxena, Recombinant vaccines for COVID-19, Hum. Vaccines Immunother. 16 (2020) 2905–2912, https://doi.org/10.1080/21645515.2020.1820808.
[216] H. Yu, W. Wu, X. Lin, Y. Feng, Polysaccharide-based nanomaterials for ocular drug delivery: a perspective, Front. Bioeng. Biotechnol. 8 (2020) 1–8, https://doi.org/10.3389/fbioe.2020.601246.
[217] L. Van de Sande, S. Cosyns, W. Willaert, W. Ceelen, Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review, Drug Deliv. 27 (2020) 40–53, https://doi.org/10.1080/10717544.2019.1704945.
[218] I. Menon, P. Bagwe, K.B. Gomes, L. Bajaj, R. Gala, M.N. Uddin, M.J. D'souza, S.M. Zughaier, Microneedles: a new generation vaccine delivery system, Micromachines 12 (2021) 1–18, https://doi.org/10.3390/mi12040435.
[219] R. Yang, Y. Deng, B. Huang, L. Huang, A. Lin, Y. Li, W. Wang, J. Liu, S. Lu, Z. Zhan, Y. Wang, R. A, W. Wang, P. Niu, L. Zhao, S. Li, X. Ma, L. Zhang, Y. Zhang, W. Yao, X. Liang, J. Zhao, Z. Liu, X. Peng, H. Li, W. Tan, A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity, Signal Transduct. Target. Ther. 6 (2021), https://doi.org/10.1038/s41392-021-00634-z.
[220] Z. Tang, N. Kong, X. Zhang, Y. Liu, P. Hu, S. Mou, P. Liljeström, J. Shi, W. Tan, J.S. Kim, Y. Cao, R. Langer, K.W. Leong, O.C. Farokhzad, W. Tao, A materials-science perspective on tackling COVID-19, Nat. Rev. Mater. 5 (2020) 847–860, https://doi.org/10.1038/s41578-020-00247-y.
[221] V. Izda, M.A. Jeffries, A.H. Sawalha, COVID-19: a review of therapeutic strategies and vaccine candidates Vladislav coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information, Clin. Immunol. 222 (2021).
[222] A.A. Latanova, S. Petkov, A. Kilpelainen, J. Jansons, O.E. Latyshev, Y.V. Kuzmenko, J. Hinkula, M.A. Abakumov, V.T. Valuev-Elliston, M. Gomelsky, V.L. Karpov, F. Chiodi, B. Wahren, D.Y. Logunov, E.S. Starodubova, M.G. Isaguliants, Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-Type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity, Sci. Rep. 8 (2018) 1–22, https://doi.org/10.1038/s41598-018-26281-z.
[223] O. Rahić, A. Tucak, N. Omerović, M. Sirbubalo, L. Hindija, J. Hadžiabdić, E. Vranić, Novel drug delivery systems fighting glaucoma: formulation obstacles and solutions, Pharmaceutics 13 (2021) 1–58, https://doi.org/10.3390/pharmaceutics13010028.
[224] M.J. Mitchell, M.M. Billingsley, R.M. Haley, M.E. Wechsler, N.A. Peppas, R. Langer, Engineering precision nanoparticles for drug delivery, Nat. Rev. Drug Discov. 20 (2021) 101–124, https://doi.org/10.1038/s41573-020-0090-8.
[225] U.B. Kompella, A.C. Amrite, R. Pacha Ravi, S.A. Durazo, Nanomedicines for back of the eye drug delivery, gene delivery, and imaging, Prog. Retin. Eye Res. 36 (2013) 172–198, https://doi.org/10.1016/j.preteyeres.2013.04.001.
[226] D.J.A. Crommelin, T.J. Anchordoquy, D.B. Volkin, W. Jiskoot, E. Mastrobattista, Addressing the cold reality of mRNA vaccine stability, J. Pharmacol. Sci. 110 (2021) 997–1001, https://doi.org/10.1016/j.xphs.2020.12.006.
[227] I. Serr, R.W. Fürst, P. Achenbach, M.G. Scherm, F. Gökmen, F. Haupt, E.M. Sedlmeier, A. Knopff, L. Shultz, R.A. Willis, A.G. Ziegler, C. Daniel, Type 1 diabetes vaccine candidates promote human Foxp3+ Treg induction in humanized mice, Nat. Commun. 7 (2016), https://doi.org/10.1038/ncomms10991.
[228] D. Chirio, E. Peira, S. Sapino, G. Chindamo, S. Oliaro-bosso, S. Adinolfi, C. Dianzani, F. Baratta, M. Gallarate, A new bevacizumab carrier for intravitreal administration: focus on stability, Pharmaceutics 13 (2021), https://doi.org/10.3390/pharmaceutics13040560.
[229] K. Battiston, I. Parrag, M. Statham, D. Louka, H. Fischer, G. Mackey, A. Daley, F. Gu, E. Baldwin, B. Yang, B. Muirhead, E.A. Hicks, H. Sheardown, L. Kalachev, C. Crean, J. Edelman, J.P. Santerre, W. Naimark, Polymer-free corticosteroid dimer implants for controlled and sustained drug delivery, Nat. Commun. 12 (2021) 1–17, https://doi.org/10.1038/s41467-021-23232-7.
[230] A. Zaqout, J. Daghfal, I. Alaqad, S.A.N. Hussein, A. Aldushain, M.A. Almaslamani, M. Abukhattab, A.S. Omrani, The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout, Int. J. Infect. Dis. 108 (2021) 116–118, https://doi.org/10.1016/J.IJID.2021.05.021.
[231] K. Maneikis, K. Šablauskas, U. Ringelevičiūtė, V. Vaitekėnaitė, R. Čekauskienė, L. Kryžauskaitė, D. Naumovas, V. Banys, V. Pečeliūnas, T. Beinortas, L. Griškevičius, Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study, Lancet Haematol. (2021), https://doi.org/10.1016/S2352-3026(21)00169-1.

[232] S. Dzieciolowska, D. Hamel, S. Gadio, M. Dionne, D. Gagnon, L. Robitaille, E. Cook, I. Caron, A. Talib, L. Parkes, È. Dubé, Y. Longtin, Covid-19 vaccine acceptance, hesitancy, and refusal among Canadian healthcare workers: a multicenter survey, Am. J. Infect. Control (2021), https://doi.org/10.1016/J.AJIC.2021.04.079.

[233] O. Sharma, A.A. Sultan, H. Ding, C.R. Triggle, A review of the progress and challenges of developing a vaccine for COVID-19, Front. Immunol. 11 (2020) 1–17, https://doi.org/10.3389/fimmu.2020.585354.

[234] A. Tauzin, M. Nayrac, M. Benlarbi, S.Y. Gong, R. Gasser, G. Beaudoin-Bussières, N. Brassard, A. Laumaea, D. Vézina, J. Prévost, S.P. Anand, C. Bourassa, G. Gendron-Lepage, H. Medjahed, G. Goyette, J. Niessl, O. Tastet, L. Gokool, C. Morrisseau, P. Arlotto, L. Stamatatos, A.T. McGuire, C. Larochelle, P. Uchil, M. Lu, W. Mothes, G. De Serres, S. Moreira, M. Roger, J. Richard, V. Martel-Laferrière, R. Duerr, C. Tremblay, D.E. Kaufmann, A. Finzi, A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses, Cell Host Microbe 29 (2021) 1137–1150, https://doi.org/10.1016/J.CHOM.2021.06.001, e6.

[235] M.J. Fisher, G. Psevdos, Asymptomatic SARS-CoV-2 infection following first dose mRNA-1273 COVID-19 vaccine in a veterans affairs long term care facility, Am. J. Infect. Control (2021), https://doi.org/10.1016/J.AJIC.2021.06.010.

[236] K. Wu, A.P. Werner, M. Koch, A. Choi, E. Narayanan, G.B.E. Stewart-Jones, T. Colpitts, H. Bennett, S. Boyoglu-Barnum, W. Shi, J.I. Moliva, N.J. Sullivan, B.S. Graham, A. Carfi, K.S. Corbett, R.A. Seder, D.K. Edwards, Serum neutralizing activity elicited by mRNA-1273 vaccine, N. Engl. J. Med. 384 (2021) 1468–1470, https://doi.org/10.1056/NEJMC2102179.

[237] V.J. Hall, S. Foulkes, A. Saei, N. Andrews, B. Oguti, A. Charlett, E. Wellington, J. Stowe, N. Gillson, A. Atti, J. Islam, I. Karagiannis, K. Munro, J. Khawam, M.A. Chand, C.S. Brown, M. Ramsay, J. Lopez-Bernal, S. Hopkins, N. Andrews, A. Atti, H. Aziz, T. Brooks, C.S. Brown, D. Camero, C. Carr, M.A. Chand, A. Charlett, H. Crawford, M. Cole, J. Conneely, S. D'Arcangelo, J. Ellis, S. Evans, S. Foulkes, N. Gillson, R. Gopal, L. Hall, V.J. Hall, P. Harrington, S. Hopkins, J. Hewson, K. Hoschler, D. Ironmonger, J. Islam, M. Kall, I. Karagiannis, O. Kay, J. Khawam, E. King, P. Kirwan, R. Kyffin, A. Lackenby, M. Lattimore, E. Linley, J. Lopez-Bernal, L. Mabey, R. McGregor, S. Miah, E.J.M. Monk, K. Munro, Z. Naheed, A. Nissr, A.M. O'Connell, B. Oguti, H. Okafor, S. Organ, J. Osbourne, A. Otter, M. Patel, S. Platt, D. Pople, K. Potts, M. Ramsay, J. Robotham, S. Rokadiya, C. Rowe, A. Saei, G. Sebbage, A. Semper, M. Shrotri, R. Simmons, A. Soriano, P. Staves, S. Taylor, A. Taylor, A. Tengbe, S. Tonge, A. Vusirikala, S. Wallace, E. Wellington, M. Zambon, D. Corrigan, M. Sartaj, L. Cromey, S. Campbell, K. Braithwaite, L. Price, L. Haahr, S. Stewart, E.D. Lacey, L. Partridge, G. Stevens, Y. Ellis, H. Hodgson, C. Norman, B. Larru, S. Mcwilliam, A. Roynon, J. Northfield, S. Winchester, P. Cieciwa, A. Pai, P. Bakker, C. Loughrey, A. Watt, F. Adair, A. Hawkins, A. Grant, R. Temple-Purcell, J. Howard, N. Slawson, C. Subudhi, S. Davies, A. Bexley, R. Penn, N. Wong, G. Boyd, A. Rajgopal, A. Arenas-Pinto, R. Matthews, A. Whileman, R. Laugharne, J. Ledger, T. Barnes, C. Jones, N. Osuji, N. Chitalia, T. Bailey, S. Akhtar, G. Harrison, S. Horne, N. Walker, K. Agwuh, V. Maxwell, J. Graves, S. Williams, A. O'Kelly, P. Ridley, A. Cowley, H. Johnstone, P. Swift, J. Democratis, M. Meda, S. Brake, J. Gunn, A. Selassi, S. Hams, V. Irvine, B. Chandrasekaran, C. Forsyth, J. Radmore, C. Thomas, K. Brown, S. Roberts, P. Burns, K. Gajee, T. Lewis, T.M. Byrne, F. Sanderson, S. Knight, E. Macnaughton, B.J.L. Burton, H. Smith, R. Chaudhuri, J. Aeron-Thomas, K. Hollinshead, R.J. Shorten, A. Swan, C. Favager, J. Murira, S. Baillon, S. Hamer, A. Shah, J. Russell, D. Brennan, A. Dave, A. Chawla, F. Westwell, D. Adeboyeku, P. Papineni, C. Pegg, M. Williams, S. Ahmad, A. Horsley, C. Gabriel, K. Pagget, G. Maloney, J. Ashcroft, I. Del Rosario, R. Crosby-Nwaobi, D. Flanagan, D. Dhasmana, S. Fowler, E. Cameron, L. Prentice, C. Sinclair, V. Bateman, K. McLelland-Brooks, A. Ho, M. Murphy, A. Cochrane, A. Gibson, K. Black, K. Tempeton, S. Donaldson, L. Coke, N. Elumogo, J. Elliott, D. Padgett, A. Cross, M. Mirfenderesky, S. Joyce, I. Sinanovic, M. Howard, P. Cowling, M. Brazil, E. Hanna, A. Abdelrazik, S. Brand, E.A. Sheridan, B. Wadams, A. Lloyd, J. Mouland, J. Giles, G. Pottinger, H. Coles, M. Joseph, M. Lee, S. Orr, H. Chenoweth, D. Browne, C. Auckland, R. Lear, T. Mahungu, A. Rodger, S. Warren, D. Brooking, S. Pai, R. Druyeh, E. Smith, S. Stone, S. Meisner, D. Delgado, E. Underhill, L. Keen, M. Aga, P. Domingos, S. Gormley, C. Kerrison, S. Birch, T. DeSilva, L. Allsop, S. Ambalkar, M. Beekes, S. Jose, J. Tomlinson, S. Painter, C. Price, J. Pepperell, K. James, T. Trinick, L. Moore, J. Day, A. Boulos, I. Knox, E. Defever, D. McCracken, K. Gray, A. Houston, T. Planche, R. Pritchard Jones, D. Wycherley, S. Bennett, J. Marrs, K. Nimako, B. Stewart, S.C. Bain, N. Kalakonda, S. Khanduri, A. Ashby, M. Holden, N. Mahabir, J. Harwood, B. Payne, K. Court, N. White, R. Longfellow, L.E. Hughes, M.E. Green, M. Halkes, P. Mercer, A. Roebuck, E. Wilson-Davies, L. Gallego, R. Lazarus, N. Aldridge, L. Berry, F. Game, T. Reynolds, C. Holmes, M. Wiselka, A. Higham, M. Booth, C. Duff, J. Alderton, D. Hilton, J. Powell, A. Jackson, A.J. Plant, N. Ahmed, T. Chin, M.Z. Qazzafi, A.M. Moody, R.E. Tilley, T. Donaghy, M. O'Kane, K. Shipman, R. Sierra, C. Parmar, G. Mills, D. Harvey, Y.W.J. Huang, J. Birch, L. Robinson, S. Board, A. Broadley, C. Laven, N. Todd, D.W. Eyre, K. Jeffery, S. Dunachie, C. Duncan, P. Klenerman, L. Turtle, H. Baxendale, J.L. Heeney, COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study, Lancet 397 (2021) 1725–1735, https://doi.org/10.1016/S0140-6736(21)00790-X.

[238] F.P. Polack, S.J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J.L. Perez, G.P. Marc, E.D. Moreira, C. Zerbini, R. Bailey, K.A. Swanson, S. Roychoudhury, K. Koury, P. Li, W.V. Kalina, D. Cooper, R.W. Frenck Jr., L.L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, D.B. Tresnan, S. Mather, P.R. Dormitzer, U. Şahin, K.U. Jansen, W.C. Gruber, Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine, N. Engl. J. Med. 383 (2020) 2603–2615, https://doi.org/10.1056/NEJMOA2034577.

[239] D. Rodríguez-Espinosa, J.J. Broseta, F. Maduell, J.L. Bedini, M. Vera, Humoral response of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients, Kidney Int. 100 (2021) 476, https://doi.org/10.1016/J.KINT.2021.05.018.

[240] L.J. Abu-Raddad, H. Chemaitelly, A.A. Butt, Effectiveness of the BNT162b2 covid-19 vaccine against the B.1.1.7 and B.1.351 variants, N. Engl. J. Med. (2021), https://doi.org/10.1056/NEJMC2104974.

[241] A. Holzworth, P. Couchot, W. Cruz-Knight, M. Brucculeri, Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine, Kidney Int. 100 (2021) 463, https://doi.org/10.1016/J.KINT.2021.05.007.

[242] K.S. Park, X. Sun, M.E. Aikins, J.J. Moon, Non-viral COVID-19 vaccine delivery systems, Adv. Drug Deliv. Rev. 169 (2021) 137–151, https://doi.org/10.1016/j.addr.2020.12.008.

[243] Y. Herishanu, I. Avivi, A. Aharon, G. Shefer, S. Levi, Y. Bronstein, M. Morales, T. Ziv, Y. Shorer Arbel, L. Scarfò, E. Joffe, C. Perry, P. Ghia, Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia, Blood 137 (2021) 3165–3173, https://doi.org/10.1182/BLOOD.2021011568.

[244] L.P. Samaranayake, C.J. Seneviratne, K.S. Fakhruddin, Coronavirus disease 2019 (COVID-19) vaccines: a concise review, Oral Dis. (2021) 1–11, https://doi.org/10.1111/odi.13916.

[245] L. Au, A. Fendler, S.T.C. Shepherd, K. Rzeniewicz, M. Cerrone, F. Byrne, E. Carlyle, K. Edmonds, L. Del Rosario, J. Shon, W.A. Haynes, B. Ward, B. Shum, W. Gordon, C.L. Gerard, W. Xie, N. Joharatnam-Hogan, K. Young, L. Pickering, A.J.S. Furness, J. Larkin, R. Harvey, G. Kassiotis, S. Gandhi, G. Kassiotis, S. Gandhi, C. Swanton, C. Swanton, C. Fribbens, K.A. Wilkinson, R.J. Wilkinson, D.K. Lau, S. Banerjee, N. Starling, I. Chau, L. Au, A. Fendler, S.T.C. Shepherd, F. Byrne, B. Shum, C. Gerard, K. Young, L. Pickering, A.J.S. Furness, J. Larkin, G. Kassiotis, K.A. Wilkinson, R.J. Wilkinson, S. Banerjee, N. Starling, I. Chau, S. Turajlic, S. Turajlic, Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2, Nat. Med. (2021), https://doi.org/10.1038/s41591-021-01387-6.